Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification

ABSTRACT

Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.

FIELD OF THE INVENTION

The present invention relates to methods for the treatment of disordersof the central nervous system (CNS) and the eye. In particular, thepresent invention relates to the use of compositions comprising acompound capable of modulating a target gene or gene product for thepreparation of a pharmaceutical composition for the treatment ofdisorders of the CNS and/or the eye, wherein the composition is designedto be administered outside the blood-CNS and the blood-retina barriers.The instant invention further relates to methods of identifying andisolating nucleic acid molecules encoding polypeptides involved in CNSdisorders or of the eye, methods for diagnosing said disorders as wellas to transgenic animals, wherein the expression of target genesidentified in accordance with the method of the invention has beenmodulated. In addition, the present invention relates to methods ofidentifying and isolating drugs that are particularly useful for thetreatment of disorders related to the CNS and/or the eye.

Several documents are cited throughout the text of this specification.Each of the documents cited herein (including any manufacturer'sspecifications, instructions, etc.) are hereby incorporated herein byreference; however, there is no admission that any document cited isindeed prior art as to the present invention.

BACKGROUND ART

A variety of approaches currently exist for delivering biologicallyactive agents to the CNS and/or the eye. These include, among possibleothers, oral administration, intravenous-, intramuscular- andtranscutaneous administration as well as intra-bulbous injection orapplication as eye-drops. If the drug is delivered into the systemiccirculation, it is being carried to all internal organs and tissues andit has to pass through the blood-brain and/or blood retina barrier (inorder to access the CNS and/or the inner parts of the eye). Obviously,all other organs are being exposed to the drug, which may lead to a highincidence of side effects, particularly when the drug exerts its effectson target genes or gene products, which are not specific for thedisorder to be treated and/or the target cell or tissue.

Another strategy often employed in brain delivery is the use of invasivemethods such as intraventricular infusion systems, intracerebral(polymeric) implants, transplantation of genetically engineeredprotein-secreting cells and cell implants. These methods areunfortunately only effective for drug delivery to the surface of thebrain or to cells immediately adjacent to the depot or infusion site andcan be used for example in the treatment of carcinomatous infiltrationof the meninges. However, these methods have many limitations becauseeffective drug concentrations in brain parenchyma cannot be achieved.

Like the human central nervous system the human eye is an organcharacterized by high complexity and the coordinated functioning ofnumerous specific structures and tissues. Both are protected by barriers(tear secretion, enzymes, transport mechanisms, blood-retina andblood-CNS barrier) against harmful environmental influences. Like theblood-brain barrier, the blood-retina barrier also represents aphysiological barrier for the uptake of medication by the inner part ofthe eye, and makes pharmacological therapy of ocular diseases verydifficult indeed—if at all possible—at the present state of technology.

Medication currently available on the market for the treatment ofdisorders of the CNS including ophthalmological diseases is thereforealmost exclusively available for treatment of clinical symptoms oftenassociated with side effects due to the high doses necessary. A causaltherapy of the CNS, and particularly of the back sections of the eye,was not possible apart from the injections. Furthermore, the currentstate of information on the complex molecular metabolicinterrelationship underlying the etiology of retinal diseases ofmulti-factorial origin is only limited. Consequently, medicamentsavailable on the market are suitable to treat the symptoms of suchdiseases only.

In view of the need of therapeutic means for the treatment of diseasesrelated to CNS and/or the eye, the technical problem of the presentinvention is to provide means and methods for the identification andmodulation of genes involved in disorders of the CNS and/or the eye.More specifically, the technical problem of present invention is toprovide non-invasive methods for the controlled modulation of targetgenes and gene products in the mammalian CNS and/or eye while overcomingthe blood-brain and/or blood retina barrier without injuring it.

The solution to said technical problem is achieved by providing theembodiments characterized in the claims, and described further below.

SUMMARY OF THE INVENTION

The present invention is directed to a method for the treatment of adisorder of the central nervous system (CNS) and/or the eye comprisingadministering to a subject a composition comprising a compound capableof modulating a target gene or gene product in a therapeuticallyeffective amount, wherein said composition is administered outside theblood-brain and/or the blood-retina barriers. In particular, saidcomposition can comprise one or more double-strandedoligoribonucleotides (dsRNA), which mediate an RNA interference of thecorresponding mRNA of one or more target genes.

In another aspect, the present invention is directed to a method ofidentifying and isolating a nucleic acid molecule encoding a polypeptideinvolved in a disorder of the CNS and/or the eye comprising the stepsof:

-   (a) culturing a cell, tissue or non-human animal under stress    conditions which lead to simulation of a pathological condition    related to a CNS or eye disorder;-   (b) isolating nucleic acids and/or proteins from a sample of said    cell, tissue or animal;-   (c) comparing the expression or activity profile of at least one of    said nucleic acids and/or proteins with that of a corresponding    non-treated cell, tissue or animal, and/or with that of a cell,    tissue or animal, which has been treated under different stress    conditions;-   (d) determining at least one nucleic acid and/or protein which is    differentially expressed, whereby a change of expression or of the    active amount of said at least one nucleic acid or activity of at    least one of said proteins or an altered localization of the protein    is indicative for its role in a disorder of the CNS or eye.

The present invention also relates to nucleic acid molecules obtainableby the method described above, particularly if the encoded polypeptideis involved in angiogenesis and/or neovascularization and/or retinaldisorder as well as to vectors comprising such nucleic acid moleculesand host cells comprising said vector.

The present invention is also directed to a method for the production ofa polypeptide capable of inducing a responsive change in a phenotypecomprising culturing said host cell under conditions allowing theexpression of the polypeptide and recovering the produced polypeptidefrom the culture as well as to polypeptides obtainable by said method orencoded by the nucleic acid molecules mentioned above.

Furthermore, the present invention relates to an antibody specificallyrecognizing such a polypeptide and pharmaceutical and/or diagnosticcompositions comprising such an antibody or any one of the abovedescribed nucleic acid molecules, nucleic acid molecules which arecomplementary to such a nucleic acid molecules, vectors, host cells,and/or polypeptides, and optionally a pharmaceutically acceptablecarrier and suitable means for detection, respectively.

In addition, the present invention is directed to methods for treating adisorder of the CNS and/or the eye comprising administering to thesubject said pharmaceutical compositions in an effective dose,

Futhermore, the present invention relates to a method for detectingexpression of a gene involved in a disorder of the CNS and/or eyecomprising:

-   (a) obtaining mRNA from a cell;-   (b) incubating the mRNA so obtained with a probe comprising a    nucleic acid molecule described above or a fragment thereof under    hybridizing conditions; and-   (c) detecting the presence of mRNA hybridized to the probe; or-   (a) obtaining a cell sample from the subject;-   (b) contacting the cell sample so obtained with an antibody    described above; and-   (c) detecting the presence of the antibody bound to the protein    encoded by said gene.

The invention furthermore is directed to a method for diagnosing in asubject said disorder or a predisposition to such disorder whichcomprises:

-   (a) isolating DNA from patient suffering from the disorder;-   (b) digesting the isolated DNA of step (a) with at least one    restriction enzyme;-   (c) electrophoretically separating the resulting DNA fragments on a    sizing gel;-   (d) incubating the resulting gel with a probe comprising a nucleic    acid molecule of the invention or a fragment thereof labelled with a    detectable marker;-   (e) detecting labelled bands on a gel which have hybridized to the    probe as defined to create a band pattern specific to the DNA of    patients of the disorder;-   (f) preparing subject's DNA by steps (a) to (e) to produce    detectable labeled bands on a gel; and-   (g) comparing the band pattern specific to the DNA of patients of    the disorder of step (e) and the subject's DNA of step (f) to    determine whether the patterns are the same or different and to    diagnose thereby the disorder or a predisposition to the disorder,    if the patterns are the same; or-   (a) analyzing a sample of nucleic acids of a subject by means of a    diagnostic chip, primer extension, single nucleotide polymorphisms    or sequencing comprising a nucleic acid molecule as described above;    and-   (b) comparing the result with that of a sample obtained from a    patient suffering from the disorder;    wherein the identity of expression profil and/or nucleotide sequence    is indicative for the disorder.

In further embodiment, the present invention relates to a method ofdetermining whether a test substance has an effect on a nucleic acidmolecule or polypeptide involved in a CNS or eye disorder comprising thesteps:

-   (a) contacting a cell which expresses the target gene or gene    product identified and isolated in accordance with the above    decribed method with a compound to be screened; and-   (b) determining if the compound modulates the expression or the    activity of said taregt gene or gene product.

In a further aspect, the present invention relates to a drug or prodrugfor the treatment of a disorder as defined above comprising:

-   (a) synthezising a test substance or a collection of test    substances;-   (b) subjecting said the test substance or collection of test    substances to the screening method of the invention; and-   (c) producing a compound identified as a modulator of a target gene    or gene product or a derivative thereof.

In addition, the present invention is directed to a transgenic non-humananimal which displays an aberrant expression or activity of the targetgene or gene product definend above and to its use for a process in drugdiscovery for the treatment of said disorder.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the use of a compound capable ofmodulating a target gene or gene product for the preparation of apharmaceutical composition for the treatment of a disorder of thecentral nervous system (CNS) and/or the eye, wherein said composition isdesigned to be applied outside the blood-CNS and/or blood-retinabarriers.

In one aspect, the present invention is based on the surprising findingthat the blood-retina barrier could be overcome by the administration ofcompounds not considered to be capable of doing so in the therapy ofocular diseases by specific modulation of protein function in thetissues of the eye. Due to the functional similarity of the blood-retinabarrier to the blood-brain barrier, providing an improved method toovercome the blood-retina barrier with the aim to treat a given eyedisease is expected to be suitable for the treatment of CNS disorders,too.

Hence, in accordance with the present invention the compositionscomprising a compound capable of modulating a target gene or geneproduct in the CNS or the eye are preferably designed to be administeredwithout any substantial, i.e. substantially effective amount ofdelivery-enhancing agents facilitating passage of compounds through theblood-brain barrier and/or without the necessity of applying invasivemethods and devices; see, e.g., those compounds, methods and devicesdescribed in U.S. 2002183683 and WO03/000018. However, for someembodiments, which represent independent aspects of the invention, suchas the use of compounds mediating RNA interference, the use of suchmethods and compounds may be encompassed for the enhanced and controlleddelivery of a compound capable of modulating a target gene or geneproduct into the mammalian CNS and/or eye while circumventing theblood-brain and blood-retina barriers.

Those later embodiments are based, inter alia, on the provision of novelmethods that overcome the difficulty of the application of conventionalexperimental strategies for the identification of genes, which cause CNSdisorders and/or eye diseases, and their validation as targets fordiagnosis and for pharmacological intervention strategies. This appliesespecially for AMD, since the symptoms of this disorder appear onlylate, generally in the 7^(th) decade of life. The current state ofknowledge regarding the pathological metabolic interrelationships is notsufficient for the medical treatment of most CNS and eye diseases.Suitable animal or cell culture models are not available for suchdiseases, due to the complexity of the disease patterns and the lack ofappropriate strategies for simple intervention and manipulation in theCNS and at the eye.

Hence, in one important aspect, the present invention relates to a cell,tissue and animal model based assay for the identification and isolationof target genes and gene products involved in disorders of the CNSand/or the eye and their use as targets for therapeutic interventionand/or diagnosis of such disorders.

Examples for CNS disorders are, for example, Alzheimer's disease,Parkinson disease, depression, bipolar disorder, schizophrenia, amnesia,migraine-headache, stroke, insomnia, alcohol abuse, anxiety, obsessivecompulsive disorder, cerebral acquired human immuno-deficiency syndrome,chronic pain and many others.

The compositions of the invention may be administered locally orsystemically e.g., intravenously. Preparations for parenteraladministration include sterile aqueous or non-aqueous solutions,suspensions, and emulsions. Examples of non-aqueous solvents arepropylene glycol, polyethylene glycol, vegetable oils such as olive oil,and injectable organic esters such as ethyl oleate. Aqueous carriersinclude water, alcoholic/aqueous solutions, emulsions or suspensions,including saline and buffered media Parenteral vehicles include sodiumchloride solution, Ringer's dextrose, dextrose and sodium chloride,lactated Ringer's, or fixed oils. Intravenous vehicles include fluid andnutrient replenishers, electrolyte replenishers (such as those based onRinger's dextrose), and the like. Preservatives and other additives mayalso be present such as, for example, antimicrobials, anti-oxidants,chelating agents, and inert gases and the like. Furthermore, thepharmaceutical composition of the invention may comprise further agentssuch as interleukins or interferons depending on the intended use of thepharmaceutical composition.

In accordance with the present invention the pharmaceutical compositionsare administered to a subject in an effective dose of between about 0,1μg to about 10 mg units/day and/or units/kg body weight; see also infra.Furthermroe, the appropriate dosage regimen can be determined accordingto Example 21.

In a preferred embodiment, the disorder to be treated is related to eye.Such disorders include chorioretinitis and herpes retinitis, which maybe considered as acquired forms of retinal disease, the majority ofretinal disease disorders are reduced to a genetic predisposition. Theseinclude for example primary retinal detachment (ablatio retinae),retinal blastoma, retinal astrocytoma (Bourneville-Pringle),angiomatosis retinae (Hippel-Lindau), Coat's disease (exudativeretinitis), Eale's disease, central serous retinopathy, ocular albinism,retinitis pigmentosa, retinitis punctata albescens, Usher syndrome,Leber's congenital amaurosis, cone dystrophy, vitelliform maculardegeneration (Best's disease), juvenile retinoschisis, North Carolinamacular dystrophy, Sorsby's fundus dystrophy, Doyne's honey comb retinaldystrophy (Malattia Leventinese), Stargardt's disease, Wagnervitreoretinal degeneration or Age-related macular degeneration (AMD) aswell as single-gene retinopathies like Morbus Best or Morbus Stargardt.Various genetic defects are known which lead or predispose to this widerange of eye disease phenotypes.

Some of these clinical phenotypes are characterized by a pathological denovo generation of blood vessels, which is called neoangiogenesis orneovascularization. Starting from the choriokapillaris, the growth ofnew blood vessels into the inner eye then leads to an increasingdegeneration of photoreceptor cells in the affected areas of the humanretina. In the field of opthalmology, one can distinguish between twoforms of neovascularization: subretinal (choroidal=CNV)neovascularization and retinal neovascularization. Subretinalneovascularization, which is also called subfoveal neovascularization,is associated with degenerative disorders like Makular degeneration andcharacterized by loss of visual acuity and metamorphopsy. On the otherhand, retinal neovascularization, vitreous body or Irisneovascularization is associated with ischemic processes (e.g. retinalvasculitis and diabetic retinopathy). Furthermore, neoangiogenesis is animportant pathomechanism in different, non ophthalmological diseasepatterns such as tumor growth, arthritis and diabetic nephropathy.Therefore, in a preferred embodiment of the methods and uses of thepresent invention said disorder to be treated is related to angiogenesisand/or neovascularization and particularly preferred to the retinalpigment epithelium (RPE), neurosensory retina and/or choriodea. Mostpreferred, the disorder is wet age-related macular degeneration (AMD) ordiabetic retinopathy.

The following description deals with AMD as example for a complex eyedisease with a genetic component. Considering the wet form of AMD, italso serves as an example for a disease pattern, which is characterizedby a distinct neovascularization. The example shall illustrate theassociated technical problems with reference to the study of molecularcauses and the development of diagnostic and pharmacologicalintervention strategies.

AMD, which can be thought as a sub-type of retinal degeneration, is themost common cause of visual morbidity in the developed world with aprevalence increasing from 9% in persons over 52 years to more than 25%in persons over the age of 75 (Paetkau et al. 1978, Leibowitz et al.1980, Banks and Hutton 1981, Ghafour et al. 1983, Hyman 1987, Hyman etal. 1983, Grey et al. 1989, Yap and Weatherill 1989, Heiba et al. 1994).

An early stage in the evolution of AMD pathology is accompagnied by anincreasing accumulation of yellowish lipofuscin-like particles withinthe retinal pigment epithelium (RPE; Feeney 1978). It is thought thatthese particles represent remnants of undigested phagocytosedphotoreceptor outer segment membranes which, in the normal process, areexcreted basally through Bruch's membrane into the choriocapillaris.Over time, accumulation of lipofuscin-like particles affect Bruch'smembrane and lead to its progressive destruction (Hogan and Alvarado1967, Sarks 1976, Feeney-Burns and Ellersieck 1985, Pauleikhoffet al.1990). The deposits in the RPE and Bruch's membrane consists largely oflipids although their exact composition may vary between individualswith some deposits revealing more polar phospholipids while otherscontain predominantly apolar neutral lipids.

These individual differences in drusen composition are thought to be thebasis for the clinical heterogeneity in AMD (Green et al. 1985). Whilesome patients present with an ingrowth of vessels from thechoriocapillaris through Bruch's membrane (neovascularization) (Bressleret al. 1982), others show pigment epithelial detachment due toexcudation underneath the RPE (Gass 1967, Green et al. 1985), and athird group of patients experiences a slow decrease of visual loss dueto atrophic changes in the RPE and the overlying sensory neuroretina(Maguire and Vine 1986).

Although much less common the excudative/neovascular form of AMDaccounts for more than 80% of blindness with a visual acuity of ≦20/200(Bressler et al. 2002). In contrast to the above described “dry” form ofAMD, the exudative “wet” AMD is associated with a choroidalneovascularization (CNV), leading to blindness and, thus, to a loss oflife quality (followed by psychic disorders, increased risk of injuryetc; Bressler et al. 2002). There is a high risk of developing (>40%)CNV in the second eye within 5 years of the development of CNV-AMD inthe first eye (Bressler et al. 2002). Neovascular AMD is characterizedby choroidal neovascular lesions. These lesions develop when abnormalblood vessels from the choroid grow and proliferate through breaks inthe Bruch membrane to beneath the retinal pigment epithelium (Bressleret al. 2002, Campochiaro et al. 1999). The abnormal leakage from thesevessels can result in hemorrhage or detachment of the retinal pigmentepithelium or the neurosensory retina (which overlies the retinalpigment epithelium). Accompanying scar formation can replace retinaltissue and result in permanent vision loss.

AMD is a complex disease caused by exogenous as well as endogenousfactors (Meyers and Zachary 1988; Seddon et al. 1997). In addition toenvironmental factors, several personal risk factors such ashypermetropia, light skin and iris colour, elevated serum cholesterollevels, hypertension or cigarette smoking have been suggested (Hyman etal. 1983, Klein et al. 1993, Sperduto and Hiller 1986, The Eye DiseaseCase-Control Study Group 1992, Bressler and Bressler 1995). A geneticcomponent for AMD has been documented by several groups (Gass 1973,Piguet et al. 1993, Silvestri et al. 1994) and has lead to thehypothesis that the disease may be triggered by environmental/individualfactors in those persons who are genetically predisposed. The number ofgenes which, when mutated, can confer susceptibility to AMD is not knownbut may be numerous.

The late onset of symptoms generally in the 7th decade of life as wellas the clinical and likely genetic heterogeneity make it difficult toapply conventional approaches for the identification of genespredisposing to AMD. Due to the complexity of the clinical phenotype, itmay be assumed that the number of genes is large, which, when mutatedcontribute to AMD susceptibility.

With recent physical approaches for the treatment of AMD such as laserphotocoagulation, photodynamic therapy (using verteprofin, trade nameVisudyne®, Novartis), irradiation or surgical therapies, success wasonly achieved with a moderate percentage of the patients (Bressler etal. 2002, Yuzawa et al. 2001).

Hence, the methods, uses and compositions of the present inventiondescribed herein represent an important improvement and alternativetherapeutic intervention for the treatment of this particular disease aswell as of others. For those embodiments the pharmaceutical compositionsare preferably designed to be effective in (and applied to) theposterior segment of the eye, preferably in a form designed to beapplied outside the retinal region of the blood-retina barrier.

In one embodiment of the invention said compound is aninhibitor/antagonist of said target gene or gene product and preferablyinhibits the expression of a gene or the activity of a gene productinvolved in angiogenesis and/or neovascularization; see supra.

The term “antagonist/inhibitor” in accordance with the present inventionincludes chemical agents that modulate the action of a gene or theactivity of a gene product either through altering its enzymaticactivity or through modulation of expression, e.g., by affectingtranscription or translation. In some cases the antagonist/inhibitor mayalso be a substrate of a a gene product involved in the disoder or aligand binding molecule.

The term “inhibitor” includes both substances which reduce the activityof the polypeptide and those which nullify it altogether.

An “antagonist” that modulates the activity of the gene product andcauses for example a response in a cell based assay described below,refers to a compound that alters directly or indirectly the activity thegene product or the amount of active product. The effect of anantagonist may be observed as a blocking of agonist-induced activationof a target gene. Antagonists include competitive as well asnon-competitive antagonists. A competitive antagonist (or competitiveblocker) interacts with or near the site specific for agonist binding. Anon-competitive antagonist or blocker inactivates the function of thegene product by interacting with a site other than the agonistinteraction site. Preferably, the antagonist/inhibitor is small chemicalagent which directly interacts with the target gene product involved inthe disorder, preferably with a gene product involved in angiogenesisand/or neovascularization. Therefore, there will preferably be a directrelationship between the molar amount of compound required to inhibit orstimulate the target gene activity and the molar amount of gene productpresent or lacking in the cell. The compounds can be derived from apolypeptide, an anti-polypeptide antibody, an RNA molecule encoding(part of) a polypeptide or its antisense sequence, a transcriptionregulator, a ligand binding molecule, a polypeptide substrate or a knownagonist/activator or antagonist/inhibitor.

In a preferred embodiment of the present invention said antagonist isbased on nucleic acids, for example a ribozyme, antisense or sensenucleic acid molecules to said gene or gene or dsRNA molecules which arecapable of mediating RNA interference. Methods and computer programs forthe preparation rational selection of for example antisenseoligonucleotide sequences are described in the prior art; see forexample Smith, Eur. J. Pharm. Sci. 11 (2000), 191-198; Toschi, Methods22 (2000), 261-269; Sohail, Adv. Drug Deliv. Rev. 44 (2000), 23-34;Moulton, J. Comput. Biol. 7 (2000), 277-292. These procedures comprisehow to find optimal hybridization sites, and secondly on how to selectsequences that bind to for example mRNAs overexpressed in a CNS or eyedisorder. These methods can include the more empirical testing of largenumbers of mRNA complementary sequences to the more systematictechniques, i.e. RNase H mapping, use of combinatorial arrays andprediction of secondary structure of mRNA by computational methods.Structures that bind to structured RNA, i.e. aptastructures and tetheredoligonucleotide probes, and foldback triplex-forming oligonucleotidescan also be employed for the purpose of the present invention. Relatingto selection of antisense sequences by aid of computational analysis,valuable www addresses are given below.

In a particularly preferred embodiment of the present invention saidantagonist/inhibitor substantially consists of ribonucleotides whichpreferbly contain a portion of double-stranded oligoribonucleotides(dsRNA). Secondary structure prediction and in vitro accessibility ofmRNA as tools in the selection of target sites is described for examplein Amarzguioui, Nucleic Acids Res. 28 (2000), 4113-4124. Minimising thesecondary structure of DNA targets by incorporation of a modifieddeoxynucleoside: implications for nucleic acid analysis by hybridisationis described in Nguyen, Nucleic Acids Res. 28 (2000), 3904-3909.

dsRNA between 21 and 23 nucleotides in length is preferred. The dsRNAmolecule can also contain a terminal 3′-hydroxyl group and may representan analogue of naturally occurring RNA, differing from the nucleotidesequence of said gene or gene product by addition, deletion,substitution or modification of one or more nucleotides. Generalprocesses of introducing an RNA into a living cell to inhibit geneexpression of a target gene in that cell comprising RNA withdouble-stranded structure, i.e. dsRNA or RNAi are known to the personskilled in the art and are described, for in WO99/32619, WO01/68836,WO01/77350, WO00/44895, WO02/055692 and WO02/055693, the disclosurecontent of which is hereby incorporated by reference.

The target mRNA of said dsRNA is preferably encoded by gene or a cDNAobtained in accordance with the method of the present inventiondescribed below. In one embodiment the target nucleotide sequenceencodes an amino acid sequence of SEQ ID NO: 2 or 4 and/or comprises anucleotide sequence of SEQ ID NO: 1 or 3.

In one embodiment of the invention the compound to be used in thecompositions is a nucleic acid molecule or encoded by a nucleic acidmolecule and is designed to be expressed in cells of the CNS and/or eye.For those embodiments gene therapy intervention is envisaged; see alsoinfra.

In a preferred embodiment of the methods and uses of the presentinvention the composition is in a form designed to be introduced intothe cells or tissue of the CNS or eye by a suitable carrier,characterized by the application occurring outside the blood-CNS and/orblood-retina barriers, for instance as eye drops. It can also beadministered systemically, iontophoretically or by retrobulbarinjection.

Iontophoresis has been defined as the active introduction of ionisedmolecules into tissues by means of an electric current. The techniquehas been used to enhance drug delivery into tissues underlying the donorelectrode (e.g. skin) as well as to the general blood circulation, thusproviding systemic delivery of a drug to the entire body. Iontophoresisdevices require at least two electrodes, both being in electricalcontact with some portion of a biological membrane surface of the body.One electrode commonly referred to as the “donor” or “active” electrode,is the electrode from which the biologically active substance, such as adrug or prodrug, is delivered into the body. Another electrode having anopposite polarity functions to complete the electric circuit between thebody and the electrical power source. This electrode is commonlyreferred to as the “receptor” or “passive” electrode. Duringiontophoresis, an electrical potential is applied over the electrodes,in order to create an electrical current to pass through the drugsolution and the adjacent tissue. Iontophoresis has been described forthe treatment of blood-vessel related disorders (e.g. restenosis),bladder, uterus, urethra and prostate disorders. U.S. Pat. Nos.6,219,557; 5,588,961; 5,843016; 5,486,160; 5,222,936; 5,232,441;5,401,239 and 5,728,068 disclose different types of iontophoresiscatheters for insertion into hollow, tubular organs (bladder, urethraand prostate) or into blood vessels. U.S. 2002183683 suggests the methodfor delivery of active substances into the CNS.

Numerous active, often specifically expressed genes are required toperform and control the processes in the cells of the CNS and the retinaand the metabolic exchanges across the blood-CNS and blood-retinabarrier. Specific genetic activity is also necessary for maintaining thestructure and functional integrity of numerous components of thesecomplex tissues. As a consequence, this unique and highly evolved systemis especially susceptible to various genetic defects, thus leading to awide range of disease phenotypes. While studying monogenetic disordersis relatively easy, provided the patients are members of a familysufficiently large enough to allow positional cloning, theidentification of genes that contribute to multigeneic disorders orconfer or susceptibility to a disease is far more difficult.

Hence, in another aspect the present invention relates to a method ofidentifying and isolating a nucleic acid molecule encoding a polypeptideinvolved in a disorder of the CNS and/or the eye comprising:

-   (a) culturing a cell, tissue or non-human animal under stress    conditions which lead to simulation of a pathological condition    related to a CNS or eye disorder;-   (b) isolating nucleic acids and/or proteins from a sample of said    cell, tissue or animal;-   (c) comparing the expression or activity profile of at least one of    said nucleic acids and/or proteins with that of a corresponding    non-treated cell, tissue or animal, and/or with that of a cell,    tissue or animal, which has been treated under different stress    conditions;-   (d) determining at least one nucleic acid and/or protein which is    differentially expressed, whereby a change of expression or of the    active amount of said at least one nucleic acid or activity of at    least one of said proteins or an altered localization of the protein    is indicative for its role in a disorder of the CNS or eye.

First, a cell, tissue or non-human animal is cultured under stressconditions which lead to simulation of a pathological condition relatedto a CNS or eye disorder. Preferably, said method is a cell culturebased method. Preferred cells and tissue investigated (either in cultureor comprised in a test animal) are those which belong to the CNS and/oreye, for example neuronal cells, glial cells, retinal cells, etc.

In a particular preferred embodiment of the method of the presentinvention said cell is an RPE cell or an established cell line derivedfrom an RPE cell such as the cell line ARPE-19; see also infra. Theisolation of RPE cells is described, e.g., in Example 1 below. ARPE-19cell line is described in Dunn et al., Exp. Eye Res. 62 (1996), 155-169.For example, ARPE-19 cell line is partiuclarly suitable for mimickingthe repair response observed in vivo during proliferativevitreoretinopathy by vitreous treatment.

The mentioned stress condition can be generated by an aberrant supply ofthe cell, tissue or animal culture conditions and comprise, for example,oxidative stress, hypoxic culture conditions, insufficient nutritionand/or supply with growth factors, change of pH-value and/orpathophysiological concentration of rod outer segments (ROS) and/orA2-E; see also Examples 3 to 10. Preferred stress conditions are thoseconferred by pathophysiological concentration of rod outer segments(ROS) and/or A2-E. As an example the tissue of the interior segment ofthe eye can be supplied in an aberrant manner, which is a preferredembodiment of the method of the invention. Table 1 shows commonly markergenes, whose altered expression indicates apoptosis, hypoxic cultureconditions or oxidative stress and which can thereby be used to verifyand/or quantify the applied stress and the cellular response,respectively.

A further step of the method of the present invention involves isolatingthe nucleic acids and/or proteins from a sample of said cell, tissue oranimal and in a further step comparing the expression or activityprofile of at least one of said nucleic acids and/or proteins with thatof a corresponding non-treated cell, tissue or animal, and/or with thatof a cell, tissue or animal, which has been treated under differentstress conditions. The isolation of nucleic acids and proteins can bedone by methods known to the person skilled in the art and described inthe cited literature; see also Examples 11 and 12.

In the last step at least one nucleic acid and/or protein which isdifferentially expressed is determined, whereby a change of expressionor of the active amount of said at least one nucleic acid or activity ofat least one of said proteins or an altered localization of the proteinis indicative for its role in a disorder of the CNS or eye.

In one embodiment of the screening method of the invention theexpression of nucleic acids is analyzed with an expression array and/orrealtime PCR. Chip and array technology are well known to the personskilled in the art; see also Examples 14 to 20. Advances in approachesto DNA-based diagnostics are reviewed, for example, by Whitcombe et al.in Curr. Opin. Biotechnol. 9 (1998), 602-608. Furthermore, DNA chips andmicroarray technology devices, systems, and applications are describedby, e.g. Cuzin, Transfus. Clin. Biol. 8 (2001), 291-296 and Heller,Annu. Rev. Biomed. Eng. (2002), 129-153. Likewise, biomedicalapplications of protein chips is known and described in, e.g., Ng, J.Cell. Mol. Med. 6 (2002), 329-340.

In another embodiment the protein expression is analyzed with immunoblotor ELISA assay, or 2 D gel electrophoresis or MALDI-TOF and particularlypreferred antibodies are used which are specific for proteins involvedin angiogenesis and/or neovascularization.

Detailed descriptions of conventional methods, such as those employed inthe construction of vectors and plasmids, the insertion of genesencoding polypeptides into such vectors and plasmids, the introductionof plasmids into host cells, and the expression and determinationthereof of genes and gene products can be obtained from numerouspublication, including Sambrook et al., (1989) Molecular Cloning: ALaboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press.Candidate nucleic acids or encoded polypeptides identified in such amanner can be validated by expressing them and observing the phenotype.A further embodiment of the screening method therefore comprises theoverexpression or inhibition of expression of the identified candidatenucleic acid or encoded polypeptide in said cell, tissue or animal fortheir capability of inducing a responsive change in the phenotype ofsaid cell, tissue or animal, wherein said phenotype is related to adisorder of the CNS or eye.

The responsive change in the phenotype of said cells can be observed bysubjecting the cells, secreted factors thereof, or cell lysates thereof,to endothelial cell cultures; and/or analyzing different parameters likecell proliferation, electrophysiological activity, DNA synthesis,out-growth of cells, cell migration, chemokinesis, chemotaxis,development of vessels, marker gene expression or activity, apoptosisand/or vitality. Examples for such assays are:

Proliferating cell nuclear antigen assay (PCNA) or TUNEL-assay aredescribed in Montesano, R.: Regulation of angiogenesis in vitro. Eur JClin Invest, 22: 504-515, 1992. Montesano, R. et al.: Basic fibroblastgrowth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA, 83:7297-7301, 1986. Holmgren, L. et al.: Dormancy of mictrometastases:Balanced proliferation and apoptosis in the presence of angiogenesissuppression. Nature Med, 1: 149-153, 1995.

Boyden chamber assay is described in Holmgren, L. et al.: Dormancy ofmictrometastases: Balanced proliferation and apoptosis in the presenceof angiogenesis suppression. Nature Med, 1: 149-153, 1995. Albini, A. etal.: A rapid in vitro assay for quantitating the invassive potential oftumor cells. Cancer Research, 47: 3239-3245, 1987. Hu, G. et al.:Angiogenen promotes invasiveness of cultured endothelial cells bystimulation of cell-associated proteolytic activities. Proc Natl AcadSci USA, 6: 12096-12100, 1994. Alessandri, G. et al.: Mobilization ofcapillary endothelium in vitro induced by effectors of angiogenesisi invivo. Cancer res, 43: 1790-1797, 1983.

Aortic ring angiogenesis assay is described in Zuh, W. H., et al.:Regulation of vascular growth and regression by matrixmetalloproteinases in the rat aorta model of angiogenesis. Lab Invest,80: 545-555, 2000. Kruger, E A. et al.: UCN01, a protein kinase Cinhibitor, inhibits endothelial cell proliferation and angiogenichypoxic response. Invasion Metastas, 18: 209-218, 2000. Kruger, E. A. etal.: Endostatin inhibits microvessel formation in the rat aortic ringangiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000.Bauer, K. S. et al.: Inhibition of angiogenesis by thalidomide requiresmetabolic activation, which is species dependent. Biochem Pharmacol, 55:1827-1834, 1998. Bauer, K. S. et al.: Carboxyamidotriazole inhibitsangiogenesis by blocking the calcium-mediated nitric-oxidesynthase-vascular endothelial growth factor pathway. J Pharmacol ExpTher, 292: 31-37, 2000. Berger, A. C. et al.: Endothelial monocyteactivating polypeptide III induces endothelial cell apoptosis and mayinhibit tumor angiogenesis. Microvasc Res, 60: 70-80, 2000.

Saphenous vein angiogenesis assay is described in Kruger, E. A. et al.:Endostatin inhibits microvessel formation in the rat aortic ringangiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000.

Comes mircropocket assay is described in Gimbrone, E. A. et al: Tumorgrowth and neovascularization: an experimental model using the rabbitcornea. J Natl Cancer Inst, 52: 413-427, 1974. Kenyon, B. M. et al.: Amodel of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci,37: 1625-1632, 1996. Kenyon, B. M. et al.: Effects of thalidomide andrelated metabolites in a mouse corneal model of neovascularization. ExpEye Res, 64: 971-978, 1997. Proia, A. D. et al.: The effect ofangiostatic steroids and beta-cyclodextrin tetradecasulfate on cornealneovascularization in the rat. Exp Eye Res, 57: 693-698, 1993.

Chick embryo chorioallantoic membrane assay is described in Knighton, D.et al.: Avascular and vascular phases of tumor growth factor in thechicken embryo. Br J Cancer, 35: 347-356, 1977. Auerbach, R. et al.: Asimple procedure for the long-term cultivation of chicken embryos. DevBiol, 41: 391-394, 1974. Ausprunk, D. H. et al.: Differentiation ofvascular endothelium in the chick chorioallantois: A structural andautoradiographic study. Dev Biol, 38: 237-248, 1974. Nguyen, M. et al.:Quantitation of angiogenesis and antiangiogenesis in the chick embryochorioallantoic membrane. Microvasc Res, 47: 31-40, 1994.

Furthermore a sample of said cells can be treated with an inhibitorspecific for the candidate nucleic acid or encoded polypeptide to bevalidated and in a second step it is determined whether said cells,secreted factors thereof or cell lysates thereof have lost theircapability of inducing the responsive change in the phenotype observedwhen no inhibitor is used. In a preferred embodiment the phenotype isangiogenesis and/or neovascularization. As an inhibitor the moleculesdescribed above can be used. Preferably, siRNA technique is used forinhibiting the expression of the target gene. A collection of protocolsfor siRNA-mediated knockdown of mammalian gene expression, which can beadapted to a method of the invention as mentioned herein is describedfor example in Elbashir et al., Methods 26 (2002), 199-213 and Martinezet al., Cell 110 (2002), 563-574.

For the development of assays and drugs for treatment of disorderscaused by the genes it is often necessary to identify the sequence ofthose nucleic acids and/or proteins, and optionally identifying thecorresponding encoding gene or cDNA as well. Based on the specificfunctions of the cells of the CNS and/or eye specific, it is presumedthat genes, the aberrant function of which cause a CNS or eye disease,are specifically expressed in the respective tissues and cells, thusrepresenting preferred targets for drug interventions. Therefore, theidentified gene, cDNA or a fragment thereof is usually also cloned andnucleic acid molecules obtainable by the methods described herein formalso part of the invention, particularly if they encode polypeptidesinvolved in angiogenesis and/or neovascularization. Such a nucleic acidmolecule can be DNA or cDNA and be derived from a mammal and in apreferred embodiment is from a mouse or a human.

Hence, in a first set of experiments several nucleic acid moleculescould be identified which indeed were known to be involved in autosomalrecessive retinitis pigmentosa (ARRP), which inter alia is characterizedby the degeneration of retinal photoreceptor cells. For example, nucleicacid molecules could be indentified corresponding to the gene encodingthe human cyclic nucleotide gated channel alpha 1 (CNGA1, accession No.NM_(—)000087; SEQ ID NO: 1 and 2). Mutations in this gene have beendescribed to be involved in autosomal recessive retinitis pigmentosa;see Dryja et al., Proc. Nat. Acad. Sci. USA 92 (1995), 10177-10181. Inanother experiment, nucleic acid molecules corresponding to the humangene encoding the beta-subunit of rod cGMP phosphodiesterase (accessionNo. NM 000283; SEQ ID NO: 3 and 4) have been identified. Malfunction ofthis gene has also been associated with autosomal recessive retinitispigmentosa, in particular with congenital stationary night blindness 3,CSNB3. These results confirm that the method of the present inventionworks.

In another embodiment the nucleic acid molecule specifically hybridizesto one of the nucleic acid molecules described above wherein the latterencodes a mutated version of the protein which has lost its capabilityof inducing a responsive change in a phenotype. In additon oralternatively, nucleic acid molecules are encompassed of at least 15nucleotides in length and able to hybridize specifically to a nucleicacid molecule described above or with a complementary strand thereof.These nucleic acid molecules are particularly useful as probes; seeinfra.

The nucleic acid molecules described above can be contained in a vectorand preferably be operatively linked to regulatory elements permittingexpression in prokaryotic or eukaryotic host cells. Expression of saidnucleic acid molecule comprises transcription into a translatable mRNA.Regulatory elements ensuring expression in eukaryotic cells, preferablymammalian cells, are well known to those skilled in the art. Theyusually comprise regulatory sequences ensuring initiation oftranscription and optionally poly-A signals ensuring termination oftranscription and stabilization of the transcript. Additional regulatoryelements may include transcriptional as well as translational enhancers,and/or naturally associated or heterologous promoter regions.

Possible regulatory elements permitting expression in prokaryotic hostcells comprise, e.g., the P_(L), lac, trp or tac promoter in E. coli,and examples for regulatory elements permitting expression in eukaryotichost cells are the AOX1 or GALL promoter in yeast or the CMV-, SV40-,RSV-promoter, CMV-enhancer, SV40-enhancer or a globin intron inmammalian and other animal cells.

Beside elements which are responsible for the initiation oftranscription such regulatory elements may also comprise transcriptiontermination signals, such as the SV40-poly-A site or the tk-poly-A site,downstream of the nucleic acid molecule. Furthermore, depending on theexpression system used leader sequences capable of directing thepolypeptide to a cellular compartment or secreting it into the mediummay be added to the coding sequence of the polynucleotide of theinvention and are well known in the art. The leader sequence(s) is (are)assembled in appropriate phase with translation, initiation andtermination sequences, and preferably, a leader sequence capable ofdirecting secretion of translated protein, or a portion thereof, intothe periplasmic space or extracellular medium. Optionally, theheterologous sequence can encode a fusion protein including a C- orN-terminal identification peptide imparting desired characteristics,e.g., stabilization or simplified purification of expressed recombinantproduct. In this context, suitable expression vectors are known in theart such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia),pCDM8, pRc/CMV, pcDNA1, pcDNA3 (Invitrogen), or pSPORT1 (GIBCO BRL).

Preferably, the expression control sequences will be eukaryotic promotersystems in vectors capable of transforming or transfecting eukaryotichost cells, but control sequences for prokaryotic hosts may also beused. Once the vector has been incorporated into the appropriate host,the host is maintained under conditions suitable for high levelexpression of the nucleotide sequences, and, as desired, the collectionand purification of the protein so produced.

Furthermore, the present invention relates to vectors, particularlyplasmids, cosmids, viruses and bacteriophages used conventionally ingenetic engineering that comprise a nucleic acid molecule of theinvention. Preferably, said vector is an expression vector and/or a genetransfer or targeting vector. Expression vectors derived from virusessuch as retroviruses, vaccinia virus, adeno-associated virus, herpesviruses, or bovine papilloma virus, may be used for delivery of thepolynucleotides or vector of the invention into targeted cellpopulation. Methods which are well known to those skilled in the art canbe used to construct recombinant viral vectors; see, for example, thetechniques described in Sambrook, Molecular Cloning A Laboratory Manual,Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocolsin Molecular Biology, Green Publishing Associates and WileyInterscience, N.Y. (1994). Alternatively, the polynucleotides andvectors of the invention can be reconstituted into liposomes fordelivery to target cells. The vectors containing the nucleic acidmolecules of the invention can be transferred into the host cell by wellknown methods, which vary depending on the type of cellular host. Forexample, calcium chloride transfection is commonly utilized forprokaryotic cells, whereas calcium phosphate treatment orelectroporation may be used for other cellular hosts; see Sambrook,supra.

Vectors that can be used for therapeutic and/or diagnostic purposes inaccordance with the teaching of the present invention are known to theperson skilled in the art; see, e.g., heritable and inducible geneticinterference by double-stranded RNA encoded by transgenes described inTavemarakis et al., Nat. Genet. 24 (2000), 180-183. Further vectors andmethods for gene tranfer and generation of transgenic animals aredescribed in the prior art; see, e.g., adeno-associated virus relatedvectors described in Qing et al., Virol. 77 (2003), 2741-2746; humanimmunodeficiency virus type 2 (HIV-2) vector-mediated in vivo genetransfer into adult rabbit retina described in Cheng et al. Curr. EyeRes. 24 (2002), 196-201, long-term transgene expression in the RPE aftergene transfer with a high-capacity adenoviral vector described inKreppel et al., Invest. Ophthalmol. Vis. Sci. 43 (2002), 1965-1970 andnon-invasive observation of repeated adenoviral GFP gene delivery to theanterior segment of the monkey eye in vivo described in Borras et al.,J. Gene Med. 3 (2001), 437-449.

CNS gene transfer has also been described in Leone et al., Curr. Opin.Mol. Ther. 1 (1999), 487-492

Said vector in turn can be contained in a host cell. A bacterial,fungal, plant or animal cell can be used as a host but mammalian cellsare preferred, especially RPE or neurosensory retina cells.

If these host cells are cultured under conditions allowing theexpression of the polypeptide and recovering the produced polypeptidefrom the culture this constitutes a method for the production of apolypeptide capable of inducing a responsive change in a phenotype.Polypeptides encoded by a nucleic acid molecule as defined above orobtainable by this method are therefore preferred embodiments of thisinvention as well as antibodies specifically recognizing such apolypeptide. Antibodies or fragments thereof to the aforementionedpolypeptides can be obtained by using methods which are described, e.g.,in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, ColdSpring Harbor, 1988.

Furthermore, the polypeptides encoded by the identified and isolatednucleic acid molecules can be used to identify synthetic chemicalpeptide mimetics that bind to or can function as a ligand, substrate,binding partner or the receptor of the polypeptide as effectively asdoes (e.g.) the natural ligand; see, e.g., Engleman, J. Clin. Invest. 99(1997), 2284-2292. For example, folding simulations and computerredesign of structural motifs of the polypeptide can be performed usingappropriate computer programs (Olszewski, Proteins 25 (1996), 286-299;Hoffman, Comput. Appl. Biosci. 11 (1995), 675-679). Computer modeling ofprotein folding can be used for the conformational and energeticanalysis of detailed peptide and protein models (Monge, J. Mol. Biol.247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 3745). Inparticular, the appropriate programs can be used for the identificationof interactive sites of the polypeptide and its ligand or otherinteracting proteins by computer assistant searches for complementarypeptide sequences (Fassina, Immunomethods 5 (1994), 114-120. Furtherappropriate computer systems for the design of protein and peptides aredescribed in the prior art, for example in Berry, Biochem. Soc. Trans.22 (1994), 1033-1036; Wodak, Ann. N.Y. Acad. Sci. 501 (1987), 1-13;Pabo, Biochemistry 25 (1986), 5987-5991. Methods for the generation anduse of peptidomimetic combinatorial libraries are described in the priorart, for example in Ostresh, Methods in Enzymology 267 (1996), 220-234and Domer, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, athree-dimensional and/or crystallographic structure of the polypeptidecan be used for the design of mimetic inhibitors of the biologicalactivity of the protein of the invention (Rose, Biochemistry 35 (1996),12933-12944; Rutenber, Bioorg. Med. Chem. 4 (1996), 1545-1558).

The structure-based design and synthesis of low-molecular-weightsynthetic molecules that mimic the activity of a native biologicalpolypeptide is further described in, e.g., Dowd, Nature Biotechnol. 16(1998), 190-195; Kieber-Emmons, Current Opinion Biotechnol. 8 (1997),435-441; Moore, Proc. West Pharmacol. Soc. 40 (1997), 115-119; Mathews,Proc. West Pharmacol. Soc. 40 (1997), 121-125; Mukhija, European J.Biochem. 254 (1998), 433-438.

The nucleic acid molecules identified and isolated by the method of thepresent invention can also serve as a target for activators andinhibitors. Activators may comprise, for example, proteins that bind tothe mRNA of the corresponding gene, thereby stabilizing the nativeconformation of the mRNA and facilitating transcription and/ortranslation, e.g., in like manner as Tat protein acts on HIV-RNA.Furthermore, methods are described in the literature for identifyingnucleic acid molecules such as an RNA fragment that mimics the structureof a defined or undefined target RNA molecule to which a compound bindsinside of a cell resulting in retardation of cell growth or cell death;see, e.g., WO 98/18947 and references cited therein. These nucleic acidmolecules can be used for identifying unknown compounds ofpharmaceutical and/or agricultural interest, and for identifying unknownRNA targets for use in treating a disease. Alternatively, for example,the conformational structure of the RNA fragment which mimics thebinding site can be employed in rational drug design to modify knownligands to make them bind more avidly to the target. One suchmethodology is nuclear magnetic resonance (NMR), which is useful toidentify drug and RNA conformational structures. Still other methodsare, for example, the drug design methods as described in WO 95/35367,U.S. Pat. No. 5,322,933, where the crystal structure of the RNA fragmentcan be deduced and computer programs are utilized to design novelbinding compounds which can act as antibiotics.

Hence, the antagonist/inhibitor can be, for example, an antibody, anantisense nucleic acid molecule or a ligand binding molecule.Preferably, said antagonist/inhibitor interferes with change ofconformation/function of the polypeptide, most preferably with abiological activity related to angiogenesis and/or neovascularization.

The antibodies, nucleic acid molecules, inhibitors and activators usedin the compositions of the present invention preferably have aspecificity at least substantially identical to the binding specificityof the natural ligand or binding partner of the protein, in particularif stimulation is desired. An antibody or inhibitor can have a bindingaffinity to the protein of at least 10⁵ M⁻¹, preferably higher than 10⁷M⁻¹ and advantageously up to 10¹⁰ M⁻¹ in case suppression should bemediated. In a preferred embodiment, a suppressive antibody or inhibitorhas an affinity of at least about 10⁻⁷ M, preferably at least about 10⁻⁹M and most preferably at least about 10⁻¹¹ M; and an activator has anaffinity of less than about 10⁻⁷ M, preferably less than about 10⁻⁶ Mand most preferably in order of 10⁻⁵M.

In case of antisense nucleic acid molecules it is preferred that theyhave a binding affinity to those encoding the protein of at most 2-, 5-or 10-fold less than an exact complement of 20 consecutive nucleotidesof the coding sequence.

Another embodiment of this invention is a pharmaceutical compositioncomprising a nucleic acid molecule described above, a vector, a hostcell, a polypeptide and/or an antibody as defined above, and optionallya pharmaceutically acceptable carrier; see supra and infra Thosecompositions can be used in a method for treating of a disorder of theCNS or the eye comprising administering to the subject such apharmaceutical compositions in an effective dose.

Similarly the nucleic acid molecule, vector, host cell, polypeptideand/or antibody described above can be used in a diagnostic compositionthat optionally contains suitable means for detection as well.Expression of a gene involved in a disorder of the CNS or the eye can bedetected by obtaining mRNA from a cell; incubating the mRNA so obtainedwith a probe comprising a nucleic acid molecule as described above or afragment thereof under hybridizing conditions; and detecting thepresence of mRNA hybridized to the probe. On the protein level themethod for detecting expression of a gene involves obtaining a cellsample from the subject; contacting the cell sample so obtained with anantibody as defined above; and detecting the presence of antibody sobound. This way the detection of the expression of a protein encoded bya mutated nucleic acid molecule which has lost its capability to inducea responsive change in phenotype is also possible.

The invention also provides a method for diagnosing in a subject adisorder or a predisposition to such disorder of the CNS or the eyewhich comprises:

-   (a) isolating DNA from patient suffering from the disorder;-   (b) digesting the isolated DNA of step (a) with at least one    restriction enzyme;-   (c) electrophoretically separating the resulting DNA fragments on a    sizing gel;-   (d) incubating the resulting gel with a probe comprising a nucleic    acid molecule described above or a fragment thereof labelled with a    detectable marker;-   (e) detecting labelled bands on a gel which have hybridized to the    probe as defined to create a band pattern specific to the DNA of    patients of the disorder;-   (f) preparing subject's DNA by steps (a) to (e) to produce    detectable labelled bands on a gel; and-   (g) comparing the band pattern specific to the DNA of patients of    the disorder of step (e) and the subject's DNA of step (f) to    determine whether the patterns are the same or different and to    diagnose thereby the disorder or a predisposition to the disorder,    if the patterns are the same.

Another method provided by this invention for diagnosing in a subject adisorder or a predisposition to such disorder of the CNS or the eyecomprises:

-   (a) analyzing a sample of nucleic acids of a subject by means of a    diagnostic chip, primer extension, single nucleotide polymorphisms    or sequencing comprising a nucleic acid molecule as defined above,    and-   (b) comparing the result with that of a sample obtained from a    patient suffering from the disorder,    -   wherein the identity of expression profile and/or nucleotide        sequence is indicative for the disorder.

In these embodiments, the nucleic acid molecules, (poly)peptide,antibodies or compounds identified above are preferably detectablylabeled. A variety of techniques are available for labelingbiomolecules, are well known to the person skilled in the art and areconsidered to be within the scope of the present invention. Suchtechniques are, e.g., described in Tijssen, “Practice and theory ofenzyme immuno assays”, Burden, R H and von Knippenburg (Eds), Volume 15(1985), “Basic methods in molecular biology”; Davis L G, Dibmer M D;Battey Elsevier (1990), Mayer et al., (Eds) “Immunochemical methods incell and molecular biology” Academic Press, London (1987), or in theseries “Methods in Enzymology”, Academic Press, Inc. There are manydifferent labels and methods of labeling known to those of ordinaryskill in the art. Commonly used labels comprise, inter alia,fluorochromes (like fluorescein, rhodamine, Texas Red, etc.), enzymes(like horse radish peroxidase, β-galactosidase, alkaline phosphatase),radioactive isotopes (like ³²P or ¹²⁵I, biotin, digoxygenin, colloidalmetals, chemi- or bioluminescent compounds (like dioxetanes, luminol oracridiniums). Labeling procedures, like covalent coupling of enzymes orbiotinyl groups, iodinations, phosphorylations, biotinylations, randompriming, nick-translations, tailing (using terminal transferases) arewell known in the art. Detection methods comprise, but are not limitedto, autoradiography, fluorescence microscopy, direct and indirectenzymatic reactions, etc.

In addition, the above-described compounds etc. may be attached to asolid phase. Solid phases are known to those in the art and may comprisepolystyrene beads, latex beads, magnetic beads, colloid metal particles,glass and/or silicon chips and surfaces, nitrocellulose strips,membranes, sheets, animal red blood cells, or red blood cell ghosts,duracytes and the walls of wells of a reaction tray, plastic tubes orother test tubes. Suitable methods of immobilizing nucleic acids,(poly)peptides, proteins, antibodies, etc. on solid phases include butare not limited to ionic, hydrophobic, covalent interactions and thelike. The solid phase can retain one or more additional receptor(s)which has/have the ability to attract and immobilize the region asdefined above. This receptor can comprise a charged substance that isoppositely charged with respect to the reagent itself or to a chargedsubstance conjugated to the capture reagent or the receptor can be anyspecific binding partner which is immobilized upon (attached to) thesolid phase and which is able to immobilize the reagent as definedabove.

Commonly used detection assays can comprise radioisotopic ornon-radioisotopic methods. These comprise, inter alia, RIA(Radioisotopic Assay) and IRMA (Immune Radioimmunometric Assay), EIA(Enzym Immuno Assay), ELISA (Enzyme Linked Immuno Assay), FIA(Fluorescent Immuno Assay), and CLIA (Chemioluminescent Immune Assay).Other detection methods that are used in the art are those that do notutilize tracer molecules. One prototype of these methods is theagglutination assay, based on the property of a given molecule to bridgeat least two particles.

For diagnosis and quantification of (poly)peptides, polynucleotides,etc. in clinical and/or scientific specimens, a variety of immunologicalmethods, as described above as well as molecular biological methods,like nucleic acid hybridization assays, PCR assays or DNA EnzymeImmunoassays (Mantero et al., Clinical Chemistry 37 (1991), 422-429)have been developed and are well known in the art. In this context, itshould be noted that the nucleic acid molecules may also comprise PNAs,modified DNA analogs containing amide backbone linkages. Such PNAs areuseful, inter alia, as probes for DNA/RNA hybridization.

The above-described compositions may be used for methods for detectingexpression of a target gene by detecting the presence of mRNA coding fora (poly)peptide which comprises, for example, obtaining mRNA from cellsof a subject and contacting the mRNA so obtained with a probe/primercomprising a nucleic acid molecule capable of specifically hybridizingwith the target gene under suitable hybridization conditions, anddetecting the presence of mRNA hybridized to the probe/primer. Furtherdiagnostic methods leading to the detection of nucleic acid molecules ina sample comprise, e.g., polymerase chain reaction (PCR), ligase chainreaction (LCR), Southern blotting in combination with nucleic acidhybridization, comparative genome hybridization (CGH) or representativedifference analysis (RDA). These methods for assaying for the presenceof nucleic acid molecules are known in the art and can be carried outwithout any undue experimentation.

Furthermore, the invention comprises methods of detecting the presenceof a target gene product, i.e. a protein in a sample, for example, acell sample, which comprises obtaining a cell sample from a subject,contacting said sample with one of the aforementioned antibodies underconditions permitting binding of the antibody to the protein, anddetecting the presence of the antibody so bound, for example, usingimmuno assay techniques such as radioimmunoassay or enzymeimmunoassay.Furthermore, one skilled in the art may specifically detect anddistinguish polypeptides which are functional target proteins frommutated forms which have lost or altered their activity by using anantibody which either specifically recognizes a (poly)peptide which hasnative activity but does not recognize an inactive form thereof or whichspecifically recognizes an inactive form but not the correspondingpolypeptide having native activity.

The invention also encompasses a method for diagnosing in a subject apredisposition to a CNS and/or eye disorder associated with theexpression of a target gene allele; see supra. The detectable markers ofthe present invention may be labeled with commonly employed radioactivelabels, such as, for example, ³²P and ³⁵S, although other labels such asbiotin or mercury as well as those described above may be employed aswell. Various methods well-known to the person skilled in the art may beused to label the detectable markers. For example, DNA sequences and RNAsequences may be labeled with ³²P or ³⁵S using the random primer method.Once a suitable detectable marker has been obtained, various methodswell-known to the person skilled in the art may be employed forcontacting the detectable marker with the sample of interest. Forexample, DNA-DNA, RNA-RNA and DNA-RNA hybridizations may be performedusing standard procedures. Various methods for the detection of nucleicacids are well-known in the art, e.g., Southern and northern blotting,PCR, primer extension and the like. Suitable further DNA amplificationtechniques are known in the art and comprise, inter alia, Ligase Chainreaction, Strand Displacement Amplification, Nucleic Acid Sequence basedAmplification (NASBA), or Q-beta replicase.

Furthermore, the mRNA, cRNA, cDNA or genomic DNA obtained from thesubject may be sequenced to identify mutations which may becharacteristic fingerprints of target gene mutations in CNS and/or eyedisorders such as described above associated with the expression of thetarget gene or mutated versions thereof. The present invention further,comprises methods, wherein such a fingerprint may be generated by RFLPsor AFLP of DNA or RNA obtained from the subject, optionally the DNA orRNA may be amplified prior to analysis, the methods of which are wellknown in the art. RNA fingerprints may be performed by, for example,digesting an RNA sample obtained from the subject with a suitableRNA-Enzyme, for example RNase T₁, RNase T₂ or the like or a ribozymeand, for example, electrophoretically separating and detecting the RNAfragments on PAGE as described above. Preferably, hybridization (andsubsequent washing) is effected under stringent conditions; see, e.g.,Sambrook et al., loc. cit and supra

Furthermore, the present invention relates to a method as describedabove wherein said sample is or is derived from hair, blood, serum,sputum, feces or another body fluid. The sample to be analyzed may betreated such as to extract, inter alia, nucleic acid molecules,(poly)peptides, or antibodies.

The present invention also relates to kit compositions containingspecific reagents such as those described herein-before. Kits containingoligonucleotides, DNA or RNA, antibodies or protein may be prepared.Such kits are used to detect for example DNA which hybridizes to DNA ofthe target gene or to detect the presence of protein or peptidefragments in a sample. Such characterization is useful for a variety ofpurposes including but not limited to forensic analyses, diagnosticapplications, and epidemiological studies in accordance with theabove-described methods of the present invention. The recombinant targetproteins, DNA molecules, RNA molecules and antibodies lend themselves tothe formulation of kits suitable for the detection and typing of thetarget gene. Such a kit would typically comprise a compartmentalizedcarrier suitable to hold in close confinement at least one container.The carrier would further comprise reagents such as recombinant proteinor antibodies suitable for detecting the expression or activity of thetarget gene or gene product. The carrier may also contain a means fordetection such as labeled antigen or enzyme substrates or the like.

Another embodiment of this invention comprises the use of an effectivedose of a nucleic acid molecule described above or a nucleic acidmolecule which is complementary to such a nucleic acid molecule, or avector as defined previously for the preparation of a composition fortreating, preventing and/or delaying a disorder of the CNS and/or theeye in a subject by somatic gene therapy.

As used herein, the term “effective dose” means the total amount of thedrug or pro-drug that is sufficient to show a meaningful patientbenefit, i.e., treatment, healing, prevention or amelioration of acondition related to the disorder of the CNS, for exampleneovascularization, or an increase in rate of treatment, healing,prevention or amelioration of such conditions. In addition oralternatively, in particular with respect to pre-clinical testing of thedrug the term “effective dose” includes the total amount of the drug orpro-drug that is sufficient to elicit a physiological response in anon-human animal test.

As mentioned above, the vectors of the present invention may also be anexpression, a gene transfer or gene targeting vector. Gene therapy,which is based on introducing therapeutic genes into cells by ex-vivo orin-vivo techniques is one of the most important applications of genetransfer. Transgenic mice expressing a neutralizing antibody directedagainst nerve growth factor have been generated using the“neuroantibody” technique; Capsoni, Proc. Natl. Acad. Sci. USA 97(2000), 6826-6831 and Biocca, Embo J. 9 (1990), 101-108. Suitablevectors, methods or gene-delivering systems for in-vitro or in-vivo genetherapy are described in the literature and are known to the personskilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996),534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256(1992), 808-813, Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ.Res. 77 (1995), 1077-1086; Onodua, Blood 91 (1998), 30-36; Verzeletti,Hum. Gene Ther. 9 (1998), 2243-2251; Verma, Nature 389 (1997), 239-242;Anderson, Nature 392 (Supp. 1998), 25-30; Wang, Gene Therapy 4 (1997),393-400; Wang, Nature Medicine 2 (1996), 714-716; WO 94/29469; WO97/00957; U.S. Pat. No. 5,580,859; U.S. Pat. No. 5,589,466; U.S. Pat.No. 4,394,448 or Schaper, Current Opinion in Biotechnology 7 (1996),635-640, and references cited therein. In particular, said vectorsand/or gene delivery systems are also described in gene therapyapproaches in neurological tissue/cells (see, inter alia Blömer, J.Virology 71 (1997) 6641-6649) or in the hypothalamus (see, inter alia,Geddes, Front Neuroendocrinol. 20 (1999), 296-316 or Geddes, Nat. Med. 3(1997), 1402-1404). Further suitable gene therapy constructs for use inneurological cells/tissues are known in the art, for example in Meier(1999), J. Neuropathol. Exp. Neurol. 58, 1099-1110. The nucleic acidmolecules and vectors of the invention may be designed for directintroduction or for introduction via liposomes, viral vectors (e.g.adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) orother delivery systems into the cell. The introduction and genetherapeutic approach should, preferably, lead to the expression of afunctional copy of the target gene of the invention. On the other hand,if target gene expression should be reduced, the expression of theintroduced vector preferably leads to the production of an inhibitor asdecribed above, for example antisense RNA or RNAi molecules. In thoseembodiments, the nucleic acid molecules are perferably linked to celland/or tissue specific promoters, particularly preferred to promotorsdirecting the expression in the cells and tissue of the eye. Examplesfor suitable promoters include the angiopoietin 2 promotor (see inHackett, J. Cell. Physiol. 184 (2000), 275-284) and particularlypreferred promotors which are capable of targeting expression to theretinal pigment epithelium such as the tyrosinase related protein-1(Tyrp1) promoter; see Beermann, Cell Mol. Biol. 45 (1999), 961-968.

In a further aspect, the present invention also provides a method forthe screening for compounds modulating the expression or the activity ofa polypeptide involved in a disorder of the CNS or the eye. This methodinvolves contacting a cell which expresses a polypeptide as describedabove identified by the methods illustrated previously with a compoundto be screened and determining if the expression or the activity isaltered.

The amount of time necessary for cellular contact with the compound isempirically determined, for example, by running a time course with aknown modulator and measuring cellular changes as a function of time.The measurement means of the method of the present invention can befurther defined by comparing a cell that has been exposed to a compoundto an identical cell that has not been similarly expose to the compound.Alternatively two cells, one containing a functional target gene and asecond cell identical to the first, but lacking a functional target genecould be both be contacted with the same compound and compared fordifferences between the two cells. This technique is also useful inestablishing the background noise of these assays. One of average skillin the art will appreciate that these control mechanisms also allow easyselection of cellular changes that are responsive to modulation of thefunctional target gene or gene product.

The term “cell” refers to at least one cell, but includes a plurality ofcells appropriate for the sensitivity of the detection method. Cellssuitable for the present invention may be bacterial, yeast, orpreferably eukaryotic. The methods of this invention employ certaintypes of cells, certain observations of changes in aspects of thebiological state of a cell, and certain comparisons of these observedchanges. Preferred cell lines to be used in the assays of the presentinvention, especially cells and cell lines derived from the CNS or eyeof, for example human, porcine, or murine origin, are described in theexamples and in the prior art, for example human retinal pigmentepithelial cells (see e.g. Dunaief et al. Curr. Eye Res. 24 (2002),392-396), immortalized human corneal epithelial cell line (see e.g.Athmanathan et al., BMC Ophthalmol. 30 (2002), 3), and also cells of theCNS, for example human neuronal cell lines (see e.g. Li et al., J.Neurosci. Res. 71 (2003), 559-566), CNS cell line immortalized with anN-terminal fragment of SV40 large T (see e.g. Truckenmiller et al., Exp.Neurol. 175 (2002), 318-337), immortalized Z310 choroidal epithelialcell line from murine choroid plexus (see Zheng and Zhao, Brain Res. 958(2002), 371-380.

Suitable cell lines, in particular animal and human cell lines as wellas technical information on the characteristics of cell lines,cytogenetic analysis, suggestions for handling cell cultures, etc can beobtained from depository institutions, for example the American TypeCulture Collection (ATCC), P.O. Box 1549, Manassas, Va. 20108, USA andDSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH,Mascheroder Weg 1b, 38124 Braunschweig, GERMANY. Preferred are RPE cellsor RPE derived celllines such as ARPE-19, cells overexpressing or withinhibited expression of candidate genes involved in CNS or eye disordersor host cells as described previously.

In a preferred embodiment said polypeptide is expressed under thecontrol of the GGTB-promoter, which is described in van Bokhoven et al.,Genomics 38 (1996), 133-140. The test substance can be a singlechemotherapeutic agent or a mixture of chemotherapeutic agents.

The cell that is contacted with the test substance can be derived from asingle cell or a multi-cellular organism. Said multi-cellular organismcan be selected from the group consisting of a vertebrate animal, amammal, a primate, an invertebrate animal, an insect and a plant. Theabove-described cells can also be comprised in a tissue or organism,i.e. non-human animal. General methods for the screening of compoundsthat have a desired effect on a cell or organism as measured in aspecific assay are described in the prior art; see for example U.S. Pat.No. 6,165,709 and references cited herein.

Cells, non-human animals and target gene expression and/or knock outsystems can be found in the prior art and adapted for the method of thepresent invention; see for example the documents cited herein.

The cellular changes suitable for the method of the present inventioncomprise directly measuring changes in the function or quantity of thetarget gene product, or by measuring downstream effects, for example bymeasuring secondary messanger concentrations or changes in transcriptionor by changes in protein levels of genes that are transcriptionallyinfluenced by the target gene product, or by measuring phenotypicchanges in the cell. Preferred measurement means include changes in thequantity of protein, changes in the functional activiy, changes in thequantity of mRNA, changes in intracellular protein, changes in cellsurface protein, or secreted protein, or changes in Ca²⁺, cAMP or GTPconcentration. Changes in the quantity or functional activity of targetgene products are described herein. Changes in the levels of mRNA aredetected by reverse transcription polymerase chain reaction (RT-PCR), bydifferential gene expression or by microarrays. Immunoaffinity, ligandaffinity, or enzymatic measurement quantitates changes in levels ofprotein in host cells. Protein-specific affinity beads or specificantibodies are used to isolate for example ³⁵S-methionine labelled orunlabelled protein. Labelled protein is analyzed by SDS-PAGE. Unlabelledprotein is detected by Western blotting, cell surface detection byfluorescent cell sorting, cell image analysis, ELISA or RIA employingspecific antibodies. Where the protein is an enzyme, the induction ofprotein is monitored by cleavage of a flourogenic or colorimetricsubstrate.

Where the endogenous gene encodes a soluble intracellular protein,changes in the endogenous gene may be measured by changes of thespecific protein contained within the cell lysate. The soluble proteinmay be measured by the methods described herein.

The assays may be simple “yes/no” assays to determine whether there is achange in expression or function, or may comprise any one of the abovedescribed methods, for example for the detection of angiogenic activity.The assay may be made quantitative by comparing the expression orfunction of a test sample with the levels of expression or function in astandard sample. Modulators identified in this process are useful astherapeutic agents.

The above-described methods can, of course, be combined with one or moresteps of any of the above-described screening methods or other screeningmethods well known in the art. Methods for clinical compound discoverycomprises for example ultrahigh-throughput screening (Sundberg, Curr.Opin. Biotechnol. 11 (2000), 47-53) for lead identification, andstructure-based drug design (Verlinde and Hol, Structure 2 (1994),577-587) and combinatorial chemistry (Salemme et al., Structure 15(1997), 319-324) for lead optimization.

Once a drug has been selected, the method can have the additional stepof repeating the method used to perform rational drug design using themodified drug and to assess whether said modified drug displays betteraffinity according to for example interaction/energy analysis.

In a preferred embodiment of the method of the present invention, saidcell, tissue or non-human animal is a transgenic cell, tissue ornon-human animal which displays a substantially reduced or enhancedlevel of target gene expression and/or gene product activity compared toa corresponding wild-type animal. Usually, said transgenic non-humananimal displaying a reduced level of target gene activity comprises atleast one mutant allele of the target gene or a correspondingtrans-dominant allele of a different gene. Preferably, said transgenicnon-human animal is a knock-out animal.

Preferably said substantially reduced or enhanced level of target geneexpression and/or gene product activity results in an altered and aphenotypic response of the transgenic cell, tissue or non-human animal.An agonist/activator or antagonist/inhibitor will then be identified byobserving whether a candidate compound is able at a certainconcentration to revert the phenotypic response of said transgenic cell,tissue or non-human animal back to normal. In a particular preferredembodiment, said transgenic non-human animal displays a CNS and/or eyedisorder as defined above.

The assay methods of the present invention can be in conventionallaboratory format or adapted for high throughput. The term “highthroughput” (HTS) refers to an assay design that allows easy analysis ofmultiple samples simultaneously, and capacity for robotic manipulation.Another desired feature of high throughput assays is an assay designthat is optimized to reduce reagent usage, or minimize the number ofmanipulations in order to achieve the analysis desired. Examples ofassay formats include 96-well, 384-well or more-well plates, levitatingdroplets, and “lab on a chip” microchannel chips used for liquidhandling experiments. It is well known by those in the art that asminiaturization of plastic molds and liquid handling devices areadvanced, or as improved assay devices are designed, that greaternumbers of samples may be performed using the design of the presentinvention.

The test substances which can be tested and identified according to amethod of the invention may be expression libraries, e.g., cDNAexpression libraries, peptides, proteins, nucleic acids, antibodies,small organic compounds, hormones, peptidomimetics, PNAs, aptamers orthe like (Milner, Nature Medicine 1 (1995), 879-880; Hupp, Cell 83(1995), 237-245; Gibbs, Cell 79 (1994), 193-198 and references citedsupra). The test substances to be tested also can be so called “fastseconds” of known drugs. The invention also relates to furthercontacting the test cells with a second test substance or mixture oftest substances in the presence of the first test substance.

In the method of the invention, said cells are preferably contained in acontainer, for example in a well in a microtiter plate, which may be a24, 96, 384 or 1586 well plate. Alternatively, the cells can beintroduced into a microfluidics device, such as those provided byCaliper (Newton, Mass., USA). In another preferred embodiment, step (b)of the method of the present invention comprises taking 2, 3, 4, 5, 7,10 or more measurements, optionally at different positions within thecontainer. In some embodiments of the method of the present invention, acompound known to activate or inhibit the target gene or gene product isadded to the medium prior to step (b).

Preferably, in a first screen said test substance is comprised in andsubjected as a collection of compounds. Said collection of compounds mayhave a diversity of about 10³ to about 10⁵. Methods for the generationand use of peptidomimetic combinatorial libraries are described in theprior art, for example in Ostresh, Methods in Enzymology 267 (1996),220-234 and Dorner, Bioorg. Med. Chem. 4 (1996), 709-715. Drug discoveryby dynamic combinatorial libraries is described, for example, in Nat.Rev. Drug Discov. 1 (2002), 26-36 and Drug Discov. Today 7 (2002),117-125.

Furthermore, the above-described methods can, of course, be combinedwith one or more steps of any of the above-described screening methodsor other screening methods well known in the art. Methods for clinicalcompound discovery comprises for example ultrahigh-throughput screening(Sundberg, Curr. Opin. Biotechnol. 11 (2000), 47-53) for leadidentification, and structure-based drug design (Verlinde and Hol,Structure 2 (1994), 577-) 587) and combinatorial chemistry (Salemme etal., Structure 15 (1997), 319-324) for lead optimization. Once a drughas been selected, the method can have the additional step of repeatingthe method used to perform rational drug design using the modified drugand to assess whether said modified drug displays better affinityaccording to for example interaction/energy analysis. The method of thepresent invention may be repeated one or more times such that thediversity of said collection of compounds is successively reduced.Preferably, the target polypeptide is involved in angiogenesis orneovascularization.

As mentioned above, the present invention provides convenient assays,preferably cell based and in vivo assays for identifying and obtainingdrugs capable of modulating the gene activity, thereby being useful as atherapeutic agent for the treatment of diseases related to CNS disordersincluding (e.g.) Schizophrenia, Parkinson's Disease, Alzheimer'sDisease, and eye diseases such as those described above. In accordancewith this, the present invention provides also a use for compounds whichhave been known in the art, properly also known to be able to modulatetarget gene activity but which hitherto have not been suggested formedical use because of the lack of knowledge of phenotypic responses ofan organism evoked by target gene activity or the lack of it.

One embodiment of this invention comprises a method for the productionof a drug or prodrug identified by such a screening as a modulator or aderivative thereof, particularly if the substance has hitherto not beenknown as a drug for the treatment of a disorder of the CNS or the eye.

Substances are metabolized after their in vivo administration in orderto be eliminated either by excretion or by metabolism to one or moreactive or inactive metabolites (Meyer, J. Pharmacokinet. Biopharm. 24(1996), 449-459). Thus, rather than using the actual compound or drugidentified and obtained in accordance with the methods of the presentinvention a corresponding formulation as a pro-drug can be used which isconverted into its active form in the patient by his/her metabolism.Precautionary measures that may be taken for the application ofpro-drugs and drugs are described in the literature; see, for review,Ozama, J. Toxicol. Sci. 21(1996), 323-329.

Furthermore, the present invention relates to the use of a compoundidentified, isolated and/or produced by any of these methods for thepreparation of a composition for the treatment of said CNS and eyedisorders. As a method for treatment the identified substance or thecomposition containing it can be administered to a subject sufferingfrom such a disorder. Compounds identified, isolated and/or produced bythe method described above can also be used as lead compounds in drugdiscovery and preparation of drugs or prodrugs.

This usually involves modifying the lead compound or a derivativethereof or an isolated compound as a to achieve (i) modified site ofaction, spectrum of activity, organ specificity, and/or (ii) improvedpotency, and/or (iii) decreased toxicity (improved therapeutic index),and/or (iv) decreased side effects, and/or (v) modified onset oftherapeutic action, duration of effect, and/or (vi) modifiedpharmakinetic parameters (resorption, distribution, metabolism andexcretion), and/or (vii) modified physico-chemical parameters(solubility, hygroscopicity, color, taste, odor, stability, state),and/or (viii) improved general specificity, organ/tissue specificity,and/or (ix) optimized application form and route by (i) esterificationof carboxyl groups, or (ii) esterification of hydroxyl groups withcarbon acids, or (iii) esterification of hydroxyl groups to, e.g.phosphates, pyrophosphates or sulfates or hemi succinates, or (iv)formation of pharmaceutically acceptable salts, or (v) formation ofpharmaceutically acceptable complexes, or (vi) synthesis ofpharmacologically active polymers, or (vii) introduction of hydrophilicmoieties, or (viii) introduction/exchange of substituents on aromates orside chains, change of substituent pattern, or (ix) modification byintroduction of isosteric or bioisosteric moieties, or (x) synthesis ofhomologous compounds, or (xi) introduction of branched side chains, or(xii) conversion of alkyl substituents to cyclic analogues, or (xiii)derivatisation of hydroxyl group to ketales, acetales, or (xiv)N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannichbases, imines, or (xvi) transformation of ketones or aldehydes to Schiffs bases, oximes, acetales, ketales, enolesters, oxazolidines,thiozolidines or combinations thereof; and (b) formulating the productof said modification with a pharmaceutically acceptable carrier.

The various steps recited above are generally known in the art. Forexample, computer programs for implementing these techniques areavailable; e.g., Rein, Computer-Assisted Modeling of Receptor-LigandInteractions (Alan Liss, New York, 1989). Methods for the preparation ofchemical derivatives and analogues are well known to those skilled inthe art and are described in, for example, Beilstein, Handbook ofOrganic Chemistry, Springer edition New York Inc., 175 Fifth Avenue, NewYork, N.Y. 10010 U.S.A. and Organic Synthesis, Wiley, New York, USA.Furthermore, peptidomimetics and/or computer aided design of appropriatederivatives and analogues can be used, for example, according to themethods described above. Methods for the lead generation in drugdiscovery also include using proteins and detection methods such as massspectrometry (Cheng et al. J. Am. Chem. Soc. 117 (1995), 8859-8860) andsome nuclear magnetic resonance (NMR) methods (Fejzo et al., Chem. Biol.6 (1999), 755-769; Lin et al., J. Org. Chem. 62 (1997), 8930-8931). Theymay also include or rely on quantitative structure-action relationship(QSAR) analyses (Kubinyi, J. Med. Chem. 41 (1993), 2553-2564, Kubinyi,Pharm. Unserer Zeit 23 (1994), 281-290) combinatorial biochemistry,classical chemistry and others (see, for example, Holzgrabe andBechtold, Pharm. Acta Helv. 74 (2000), 149-155). Furthermore, examplesof carriers and methods of formulation may be found in Remington'sPharmaceutical Sciences.

Once a drug has been selected in accordance with any one of theabove-described methods of the present invention, the drug or a pro-drugthereof can be synthesized in a therapeutically effective amount. Asused herein, the term “therapeutically effective amount” means the totalamount of the drug or pro-drug that is sufficient to show a meaningfulpatient benefit, i.e., treatment, healing, prevention or amelioration ofa condition related to disorders of the CNS and/or the eye, or anincrease in rate of treatment, healing, prevention or amelioration ofsuch conditions. In addition or alternatively, in particular withrespect to pre-clinical testing of the drug the term “therapeuticallyeffective amount” includes the total amount of the drug or pro-drug thatis sufficient to elicit a physiological response in a non-human animaltest.

Furthermore the nucleic acid molecules described above can in turn beused for the validation of test substances, lead compounds, drugs andprodrugs for the treatment of a disorder of the CNS or the eye or forthe identification and isolation of downstream genes.

The present invention also relates to a chip or array comprising a solidsupport and attached thereto one or more of the nucleic acid moleculesor encoded (poly)peptides described above, which chip or assay is usefulfor performing any one of the above described methods. Chip-based orother means for the detection of expression and/or activity of a nucleicacid molecule described above or the respective polypeptides can beprovided for in form of a kit, which constitutes a preferred embodimentof the invention. Similarly kit can be developed for the methods foridentification, production and screening of active molecules.

In a still further embodiment, the present invention relates to atransgenic non-human animal which displays an aberrant expression oractivity of the target gene and/or gene product mentioned previously oridentified and obtained by the methods described above, especially whensaid animal reproduces a disorder of the CNS and/or the eye. Preferably,said animal is a mammal.

A method for the production of a transgenic non-human animal, which isalso encompassed by the present invention, for example transgenic mouse,comprises introduction of a polynucleotide or targeting vector encodingsaid polypeptide into a germ cell, an embryonic cell, stem cell or anegg or a cell derived therefrom. The non-human animal can be used inaccordance with a screening method of the invention described herein.Production of transgenic embryos and screening of those can beperformed, e.g., as described by A. L. Joyner Ed., Gene Targeting, APractical Approach (1993), Oxford University Press. A general method formaking transgenic non-human animals is described in the art, see forexample WO 94/24274. For making transgenic non-human organisms (whichinclude homologously targeted non-human animals), embryonal stem cells(ES cells) are preferred. Murine ES cells, such as AB-1 line grown onmitotically inactive SNL76/7 cell feeder layers (McMahon and Bradley,Cell 62: 1073-1085 (1990)) essentially as described (Robertson, E. J.(1987) in Teratocarcinomas and Embryonic Stem Cells: A PracticalApproach. E. J. Robertson, ed. (Oxford: IRL Press), p. 71-112) may beused for homologous gene targeting. Other suitable ES lines include, butare not limited to, the E14 line (Hooper et al., Nature 326: 292-295(1987)), the D3 line (Doetschman et al., J. Embryol. Exp. Morph. 87:27-45 (1985)), the CCE line (Robertson et al., Nature 323: 445-448(1986)), the AK-7 line (Zhuang et al., Cell 77: 875-884 (1994)). Thesuccess of generating a mouse line from ES cells bearing a specifictargeted mutation depends on the pluripotence of the ES cells (i.e.,their ability, once injected into a host developing embryo, such as ablastocyst or morula, to participate in embryogenesis and contribute tothe germ cells of the resulting animal). The blastocysts containing theinjected ES cells are allowed to develop in the uteri of pseudopregnantnonhuman females and are born as chimeric mice. The resultant transgenicmice are chimeric for cells having either the recombinase or reporterloci and are backcrossed and screened for the presence of the correctlytargeted transgene (s) by PCR or Southern blot analysis on tail biopsyDNA of offspring so as to identify transgenic mice heterozygous foreither the recombinase or reporter locus/loci.

Methods for producing transgenic flies, such as Drosophila melanogasterare also described in the art, see for example U.S. Pat. No. 4,670,388,Brand & Perrimon, Development (1993) 118: 401-415; and Phelps & Brand,Methods (April 1998) 14: 367-379. Transgenic worms such as C. eleganscan be generated as described in Mello, et al., Embo J. 10 (1991),3959-3970, Plasterk, Methods Cell Biol 48 (1995), 59-80.

Preferably, the transgenic non-human animal comprises at least oneinactivated or suppressed wild type allele of the corresponding gene,involved in an CNS and/or eye disorder; see supra. This embodimentallows for example the study of the interaction of various mutant formsof these genes or gene products on the onset of the clinical symptomsand/or may be used to verify the involvement of said gene(s) in thedisorder to be studied. All the applications that have been hereinbefore discussed with regard to a transgenic animal also apply toanimals carrying two, three or more transgenes. It might be alsodesirable to inactivate target gene expression or function at a certainstage of development and/or life of the transgenic animal. This can beachieved by using, for example, tissue specific (see supra),developmental and/or cell regulated and/or inducible promoters whichdrive the expression of, e.g., an antisense or ribozyme directed againstthe RNA transcript encoding the target gene mRNA; see also supra. Asuitable inducible system is for example tetracycline-regulated geneexpression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad.Sci. 89 USA (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12(1994), 58-62). Similar, the expression of a mutant target gene may becontrolled by such regulatory elements. Preferably, the presence of thetransgenes in cells of the transgenic animals leads to to variousphysiological, developmental and/or morphological changes, preferably toconditions related to disorders of the CNS and/or eye such as thosedescribed above.

In another embodiment said transgenic non-human animal is used for aprocess in the discovery of drugs for the treatment of a disorder of theCNS and/or the eye. In particular, mammlian animals are preferred,especially mice and rats. Corresponding animal systems that can beadapted in accordance with the present invention are known to personskilled in the art; see, e.g., molecular biological approaches toneurological disorders including knockout and transgenic mouse modelsdescribed in Shibata et al., Neuropathology 22 (2002), :337-349.However, the widely used zebra fish may also be used since this modelsystem has also been shown to provide valuable predicitve results; see,e.g. Gerlai et al., Pharmacol. Biochem. Behav. 67 (2000), 773-782.

In a preferred embodiment of the invention the pharmaceuticalcomposition for use in the treatment of the above described CNS and/oreye disorders comprise one or more double-stranded oligoribonucleotides(dsRNA), see supra, which mediate an RNA interference of thecorresponding mRNA of one or more nucleic acid molecules which have beenshown to be involved in said disorders, and optionally apharmaceutically acceptable carrier. The method for specific inhibitionof genes by double-stranded oligoribonucleotides (dsRNA) is known fromWO 01/75164. The disclosure of this application is hereby included inthis present description.

This application describes that double-stranded oligoribonucleotides(dsRNA) induce specific degradation of mRNA after delivery to the targetcells. The specificity of this process is mediated by thecomplementarity of one of the two dsRNA strands to the mRNA of thetarget gene.

The process of gene-specific, post-transcriptional switching off ofgenes by dsRNA molecules is referred to as RNA interference (RNAi). Thisterm was originally developed by Fire and co-workers to describe theblockage of gene expression observed by delivery of dsRNA molecules tothe threadworm Caenorhabditis elegans (Fire et al., 1999). Subsequently,RNAi could also be demonstrated in plants, protozoa, insects (Kasschauand Carrington 1998) and recently also in mammalian cells (Caplen etal., 2001; Elbashir et al., 2001). The mechanism by which RNAisuppresses gene expression is not yet fully understood. Studies ofnon-mammalian cells have shown that dsRNA molecules are transformed intosmall interfering RNA molecules (siRNA molecules) by endogenousribonucleases (Bernstein et al., 2001; Grishok et al., 2001; Hamiltonand Baulcombe, 1999; Knight and Bass, 2001; Zamore et al., 2000).

Desirably, the region of the double stranded RNA that is present in adouble stranded conformation includes at least 5, 10, 20, 30, 50, 75,100 or 200. Preferably, the double stranded region includes between 15and 30 nucleotides, most preferably 20 to 25 and particularly preferred21 to 23 nucleotides, since for the specific inhibition of a targetgene, it suffices that a double-stranded oligoribonucleotide exhibits asequence of 21 to 23 nucleotides (base pairs) in length identical to thetarget gene; see, e.g., Elbashir et al., Methods 26 (2002), 199-213 andMartinez et al., Cell 110 (2002), 563-574. General means and methods forcell based assays for for identifying nucleic acid sequences thatmodulate the function of a cell, by the use of post-transcriptional genesilencing including definitions, methods for the preparation of dsRNA,vectors, selectable markers, compositions, detection means, etc., andwhich can be adapted in accordance with the teaching of the presentinvention are described in Euopean patent application EP 1 229 134 A2,the disclosure content of which is incorporated herein by reference

In contrast to the cited literature in which the use of siRNA and otherRNA based molecules is described for cell culture only, experimentsperformed in accordance with the present invention surprisinglydemonstrate that dsRNA molecules of a length of 21 to 23 nucleotides arecapbale of, after systemic application, for example by intravenousinjection, to cross the blood-retina barrier, and specificallyinactivate target genes in the tissues of the back of the eye. Thisovercoming the blood-retina barrier is all the more remarkable, becauseno experiment could demonstrate overcoming the blood-brain barrier bydsRNA so far. The methods and uses of the invention, explained below bymeans of examples, are thus suitable for the provision of animal modelswith which targets, the restricted function of which causing diseases ofthe eye, can be identified and validated. Those methods are moreoversuitable for the specific intervention in CNS and eye diseases on amolecular level, without necessitating direct application to the siteof, for example affected cells or tissue. The specificity of selectedinhibitors such as preferably RNAi for the inhibition of genes expressedspecifically in target cells minimizes the risk of unwanted sideeffects.

The dosage regimen of the pharmaceutical compositions in all of theabove described methods and uses of the present invention will bedetermined by the attending physician and clinical factors. As is wellknown in the medical arts, dosages for any one patient depends upon manyfactors, including the patient's size, body surface area, age, theparticular compound to be administered, sex, time and route ofadministration, general health, and other drugs being administeredconcurrently. A typical dose can be, for example, in the range of 0.001μg to 10 mg (or of nucleic acid for expression or for inhibition ofexpression in this range); however, doses below or above this exemplaryrange are envisioned, especially considering the aforementioned factors.Generally, the regimen as a regular administration of the pharmaceuticalcomposition should be in the range of 0.01 μg to 10 mg units per day. Ifthe regimen is a continuous infusion, it should also be in the range of0.01 μg to 10 mg units per kilogram of body weight per minute,respectively. Progress can be monitored by periodic assessment. Dosageswill vary but a preferred dosage for intravenous administration ofnucleics acids is from approximately 10⁶ to 10¹² copies of the nucleicacid molecule.

Therapeutic or diagnostic compositions of the invention are administeredto an individual in an effective dose sufficient to treat or diagnosedisorders in which modulation of a target gene or gene product isindicated. The effective amount may vary according to a variety offactors such as the individual's condition, weight, sex and age. Otherfactors include the mode of administration. The pharmaceuticalcompositions may be provided to the individual by a variety of routessuch as by intracoronary, intraperitoneal, subcutaneous, intravenous,transdermal, intrasynovial, intramuscular or oral routes. In addition,co-administration or sequential administration of other agents may bedesirable.

A therapeutically effective dose refers to that amount of compoundsdescribed in accordance with the present invention needed to amelioratethe symptoms or condition. Therapeutic efficacy and toxicity of suchcompounds can be determined by standard pharmaceutical procedures incell cultures or experimental animals, e.g., ED50 (the dosetherapeutically effective in 50% of the population) and LD50 (the doselethal to 50% of the population). The dose ratio between therapeutic andtoxic effects is the therapeutic index, and it can be expressed as theratio, LD50/ED50.

These and other embodiments are disclosed and encompassed by thedescription and Examples of the present invention. Further literatureconcerning any one of the materials, methods, uses and compounds to beemployed in accordance with the present invention may be retrieved frompublic libraries and databases, using for example electronic devices.For example the public database “Medline” may be utilized, which ishosted by the National Center for Biotechnology Information and/or theNational Library of Medicine at the National Institutes of Health.Further databases and web addresses, such as those of the European

Bioinformatics Institute (EBI), which is part of the European MolecularBiology Laboratory (EMBL) are known to the person skilled in the art andcan also be obtained using internet search engines. An overview ofpatent information in biotechnology and a survey of relevant sources ofpatent information useful for retrospective searching and for currentawareness is given in Berks, TEBTECH 12 (1994), 352-364.

The above disclosure generally describes the present invention. A morecomplete understanding can be obtained by reference to the followingspecific examples and figure which are provided herein for purposes ofillustration only and are not intended to limit the scope of theinvention. The contents of all cited references (including literaturereferences, issued patents, published patent applications as citedthroughout this application and manufacturer's specifications,instructions, etc) are hereby expressly incorporated by reference;however, there is no admission that any document cited is indeed priorart as to the present invention.

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, transgenic biology, microbiology, recombinant DNA,and immunology, which are within the skill of the art. Such techniquesare explained fully in the literature; see, for example, DNA Cloning,Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M.J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic AcidHybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription AndTranslation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of AnimalCells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells AndEnzymes (IRL Press, 1986); B. Perbal, A Practical Guide To MolecularCloning (1984); the treatise, Methods In Enzymology (Academic Press,Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller andM. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods InEnzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical MethodsIn Cell And Molecular Biology (Mayer and Walker, eds., Academic Press,London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M.Weir and C. C. Blackwell, eds., 1986).

Detailed descriptions of conventional methods, such as those employed inthe construction of vectors and plasmids, the insertion of genesencoding polypeptides into such vectors and plasmids, the introductionof plasmids into host cells, and the expression and determinationthereof of genes and gene products can be obtained from numerouspublication, including Sambrook et al., (1989) Molecular Cloning: ALaboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press.

The figure shows:

FIG. 1: eGFP-expression in retina and retinal pigment epithet (RPE) ofsystemically dsRNA-treated FVB.CG-TG(GFPU)5NAGY mice. The figure showseGFP-expression in eye paraffin sections of dsRNA-treatedFVB.Cg-Tg(GFPU)5Nagy mice. Expression in retina and retinal pigmentepithel (RPE) of systemically dsRNA-treated FVB.CG-TG(GFPU)5NAGY mice ishighest in the buffer control, slightly decreased in mice treated withnon-silencing dsRNA and clearly decreased in eGFP-specific dsRNA treatedmice (buffer control >200 μg/kg BW non-silencing dsRNA >100 μg/kg BWeGFP-specific dsRNA >200 μg/kg BW eGFP-specific dsRNA).

EXAMPLES Example 1 Isolation of Primary Porcine Retinal PigmentEpithelial Cells (RPE Cells)

The following example describes exemplary the isolation of primaryporcine RPE cells which is carried out under sterile conditions. Theisolation of RPE-cells from pork, human and cattle is in principal thesame.

Porcine eyes were obtained from a local slaughter house. After the eyeswere liberated from rests of ocular muscle, they were washed once withsterile ice cold phosphate buffered saline (1×PBS: 1.15 g/l Na₂HPO₄,0.20 g/l KH₂PO₄×H₂O, 8.00 g/l NaCl, 0.20 g/l KCl, 0.10 g/l MgCl₂, 0.10g/l CaCl₂) containing penicillin (100 U/ml) and streptomycin (100μg/ml). The eyes were sliced around the ora serrata and the ocular lensand the vitreous were removed. From the eye cups the retinae werecarefully detached with a hitch and removed after cutting the opticnerve. The retinae were used for the isolation of the rod outer segmentsas described in example 2. The remaining eye cup was covered with 1 ml1×PBS to wash the cells. The solution was rejected and the cells wereincubated in 1 to 1.5 ml of a trypsin/EDTA solution (0.25%/0.02%) for 15minutes at 37° C. The solution was rejected and the cups were againcovered with 1 ml of the trypsin/EDTA solution for 1 hour at 37° C. TheRPE cells were carefully removed by pipetting up and down and cells fromsix eyes were diluted in 20 ml cell culture medium (DMEM F12 (BioWhittaker) with 10% fetal calf serum (FCS), penicillin (100 U/ml) andstreptomycin (100 μg/ml), 2 mM glutamine, 1.5 g/ml sodium bicarbonate).The cells were centrifuged 5 minutes with 120×g at room temperature andwashed twice with the cell culture medium. Per T25 cell culture flask,cells according to three retinae were plated. To get rid of cell debristhe cells were washed with 1×PBS on the next day. For approximately oneweek RPE-cells were cultivated in cell culture medium containing 10%FCS. After they have reached confluency the culture medium wassubstituted against medium containing 2% FCS. After a further oneweek-incubation the cells were splitted on cell culture dishes in theratio 1:2 for further experimental use.

Example 2 Isolation of Rod Outer Segments (ROS) from Porcine Eyes

The ROS isolation was carried out under sterile conditions. Thirtyretinae isolated during the RPE-cell preparation (see example 1) weretransferred to 15 ml of a ice cold homogenisation buffer (containing 20%(w/v) sucrose, 20 mM tris-acetat pH 7.2, 2 mM MgCl₂, 10 mM glucose). Thesuspension was shaken gently for 1 minute, filtered 3 times throughcheesecloth to remove tissue fragments and layered on a 24 ml 25-60% w/vcontinuous sucrose gradient containing 20 mM Tris acetate pH 7.2, 10 mMglucose. Centrifugation was carried out in a Beckman SW-27 rotor at24,000 rpm for 1 hour at 4° C. The upper white-yellow band of thegradient was collected, diluted with the same volume of 10 mM Hepesbuffer pH 7.4, 115 mM NaCl, 2.5 mM KCl, 1 mM DTT, 1 mM MgCl₂, mixedcautious and centrifuged 10 minutes in a Sigma 4K15 centrifuge, 2989×g,4° C. The supernatant was removed carefully and the ROS pellet wasstored for further use at −20° C. From one retina were approximately1×10⁷ ROS isolated.

Example 3 Incubation of Primary Porcine RPE-Cells with (PhysiologicalConcentrations) of ROS

Since the incubation of RPE-cells from pork, human and cattle with ROSis in principal the same, the following example refers to the incubationof RPE cells isolated from porcine eyes (see example 2).

ROS pellet stored at −20° C. was warmed-up slowly to room temperature.According to the number of primary RPE-cells, an amount of 10 to 100 ROSper cell was taken from the ROS-suspension. During incubation, the cellculture medium was changed every day and new ROS were added.

The phagocytosis of ROS by RPE cells was controlled in parallel by twoapproaches. Approach one comprises the detection of ROS covalentlylabelled with the dual wavelength fluorescent dye SNAFL-2 (MolecularProbes, Leiden Netherlands). The acid form (pH 5) appears green-yellowwhereas the alkaline form (pH 9) appears yellow-orange. SNAFL-2 (10 μgSNAFL-2 in 1 μl dimethylformimide) was added to isolated ROS in 100 μlsucrose buffer (20% sucrose, 2 mM MgCl2, 10 mM glucose, 20 mM trisacetate pH 8.0) and the ROS were labelled for 1 hour at room temperaturein the dark with gentle stirring. The labelled ROS were diluted with thesame volume of the hepes buffer pH 8.0 spun down for 5 minutes at 2000rpm in a Heraeus Biofuge pico and washed two times with 100 μl the hepesbuffer pH 8.0. The labelled ROS were resuspended in cell culture mediumand added to the cells. After an incubation time of 4 to 8 hours cellswere washed and cell culture medium pH 9.0 was added for fluorescencemicroscopy.

In approach two ROS treated cells were washed in 1×PBS (containing Ca²⁺and Mg²⁺) and analyzed by fluorescence microscopy forautofluorescence-activity of internalized ROS.

Example 4 Post Transcriptional Gene Silencing (PTGS) of a Given TargetGene

The following example describes PTGS of a given target gene (growthfactor) X in primary cells isolated from different organisms (i.e. pork,human, cattle) or in cell lines (i.e. ARPE-19).

After optimizing the experimental conditions with respect to the dsRNAidentity, its concentration and the appropriate transfection reagent,PTGS was performed using three (to five) dsRNAs homologous to differentregions of the mRNA of the target gene synthesized either by acommercial provider (preferential Proligo) or from correspondingoligonucleotides using a commercially available kit (preferentialSilencer™ siRNA Construction Kit, Ambion). 1 ng up to 100 μg of eachsiRNA was introduced into the cells by commercially availabletransfection reagents (preferential Gene Eraser/Stratagene,Transmessenger/Qiagen, Oligofectamin/Invitrogen).

Up to five days post transfection cells were harvested for the analysisof mRNA expression profile by real time PCR and up to one week posttransfection cells were harvested for the analysis of protein expressionby western blot analysis or ELISA.

Example 5 Synthesis and Purification of A2-E

A2-E was synthesized from all-trans-retinal and ethanolamine asdescribed from Parish et al. (1998) (Parish C A, Hashimoto M, NakanishiK, Dillon J, Sparrow J.: Isolation and one-step preparation of A2E andiso-A2E, fluorophores from human retinal pigment epithelium. Proc NatlAcad Sci USA. 1998 Dec. 8;95(25):14609-13) and purifiedchromatographically on silica gel 60 thin layer chromatography platesusing the primary developing system from Eldred and Katz (1988) (EldredG E, Katz M L.: Fluorophores of the human retinal pigment epithelium:separation and spectral characterization. Exp Eye Res. 1988July;47(1):71-86). 50-150 mg retinal were dissolved in 1,5-5,5 mlethanol. 5-15 μl ethanolamine was added and stirred. While stirring 5-15μl acetic acid were slowly added. The mixture was wraped in aluminiumfoil, and stirred for two days at room temperature. The reaction mix wasdistributed 4 times into four Eppendorf tubes and concentrated todryness in a speedvac overnight. The content of two Eppendorf reactiontubes was dissolved in a total of 200-600 μl “primary developing system”(14,5 ml heptane, 8,8 ml hexane, 9,8 ml chloroform, 3 ml ether, 3 mlacetone, 14,8 ml iso-propanol, 27 ml ethanol, 2,5 ml methanol, 0,4 mlacetic acid, 7,4 ml H₂O). Then 5-15 aliquots, containing 20-60 μl each,of this solution were applied to a silica chromatography plate that wasdeveloped with the “primary developing system” for about 2 hours. A2-Ewas detected an the plates by their fluorescence upon illumination with366-nm light. The material containing A2-E was scraped off (A2-E: upperspot; iso-A2-E: lower spot) and eluted 2-3 times withchloroform/methanol/water by vortexing. The supernatants were combinedand dried in a speedvac for few hours. The dried material was taken upin 200-600 μl “primary developing system” and rechromatographed. Theextraction and the drying were also repeated. The dried material wastaken up as a A2-E stock solution in about 1 ml Me₂SO or ethanol andstored at −20° C. in the dark. Total A2-E diluted in Me₂SO or ethanolwas quantified using a molar extinction coefficient of 36,900 at 439 nm(Parish C A, Hashimoto M, Nakanishi K, Dillon J, Sparrow J.: Isolationand one-step preparation of A2E and iso-A2E, fluorophores from humanretinal pigment epithelium. Proc Natl Acad Sci USA. 1998 Dec.8;95(25):14609-13).

Example 6 Incubation of RPE Cells with A2-E and the Analysis of A2-EAccumulation

A2-E was diluted into the RPE cell culture medium to a concentration of1 to 100 μM A2-E and 0,5% Me₂SO or ethanol. With the aim to find outsub-apoptocical A2E concentrations, control incubations were done with0,5% Me₂SO or ethanol in the absence of A2-E as a negative control andwith 1 to 200 μM staurosporine as a apoptosis control. Incubation wascarried out at 37° C. with 5% CO₂ for 24 to 144 h in the darkness(wrapped in aluminium foil) once each day. Cells can also placed under alight source and exposed to light at 390 to 550 nm of various times upto 144 hours. Controls were also run with medium alone. To determine themean autofluorescence per population of RPE the intracellularfluorescence was assessed using a fluorescence microscope (Nikon;excitation 450-490 nm, emission >510 nm) and a Safire (Tecan; excitation456 nm, emission 610 nm) at various times after feeding.

Example 7 Apoptosis Assay

The following example describes the analysis of the induction ofapoptosis with the Cell Death Detection ELISA Plus (Roche) (Wyllie A H,Kerr J F, Currie A R.: Cell death: the significance of apoptosis. IntRev Cytol. 1980;68:251-306. Review). The assay based on a quantitativesandwich-enzyme-immunoassay-principle using mouse monoclonal antibodiesdirected against DNA and histones, respectively. This allows thespecific determination of mono- and oligonucleosomes which are releasedinto the cytoplasm of cells which die from apoptosis. The sample(cell-lysate, serum, culture-supernatant etc.) was placed into astreptavidin-coated microplate. Subsequently, a mixture ofanti-histone-biotin and anti-DNA-POD was added and incubated for 2hours. During the incubation period, the anti-histone antibody binds tothe histone-component of the nucleosomes and simultaneously fixes theimmunocomplex to the streptavidin-coated microplate via itsbiotinylation. Additionally, the anti-DNA-POD antibody reacts with theDNA-component of the nucleosomes. After removal of unbound antibodies bya washing step, the amount of nucleosomes was quantified by the PODretained in the immunocomplex. POD was determined photometrically withABTS (2,2′-Azino-di[3-ethyl-benz-thiazolin-sulfonat]) as substrate.

Example 8 Induction of Hypoxia

RPE cells were incubated in an incubator (Heracell, Kendro) maintainedat 37° C. and 95% air, 5% CO₂ by vol (normoxic conditions) to 100%confluence (about 10⁷ cells/100-mm plate). Cells were then subjected tohypoxic conditions by placing them in an automatic CO₂/O₂ incubator (B5061 EC/O₂, Kendro) maintained at 37° C. and O₂ levels ranging from 0 to8%, 5% CO₂, 95 to 87% N₂ (N₂ to balance) for 1 h to 7 days. Uninducedcells remained in normoxic conditions. PO₂ and PCO₂ of the medium weremeasured in a blood gas analyzer (Corning model 178). Normoxic valueswere as follows: pH=7.2+/−0.1, PO₂=39.3+/−0.6 mmHg and PCO₂=131.5+/−0.9mmHg. Hypoxic values were as follows: pH=7.2+/−0.1, PO₂=7 to 35+/−1.1mmHg and PCO₂=14.9+/−1.2 mmHg (Liu et al., 1995; Palmer et al., 1998)(Liu Y, Cox S R, Morita T, Kourembanas S.: Hypoxia regulates vascularendothelial growth factor gene expression in endothelial cells.Identification of a 5′ enhancer. Circ Res. 1995 September;77(3):638-43;Palmer L A, Semenza G L, Stoler M H, Johns R A.: Hypoxia induces type IINOS gene expression in pulmonary artery endothelial cells via HIF-1. AmJ. Physiol. 1998 February;274(2 Pt 1):L212-9).

Example 9 Limitation of Essential Factors

The following example describes the cultivation of RPE cells in amodified Dulbecco's modified Eagle's medium (high glucose, LifeTechnologies, Inc.) for inducing stress in RPE cells by lackingessential factors. In normal RPE cell culture the cells grow in amodified Dulbecco's modified Eagle's medium. (high glucose, LifeTechnologies, Inc.) supplemented with 2% heat inactivated fetal calfserum (Roche), 100 units/ml penicillin, 100 μg/ml streptomycin, 1×non-essential amino acids, 2 mM L-glutamine, ans 1 mM sodium pyruvate(all Life Technologies, Inc.) in a humidified atmosphere containing 5%CO₂ at 37° C. Normal cell culture media contains different anorganicsalts and is added with vitamins, amino acids, glucose, nucleotides undmany other substances. Most cells need for growing blood serum, such asfetal calf serum. The serum supplements proteins, hormons, growthfactors, and intermediate products. For limitting these essentialfactors cells were cultured in a serum free medium. Additionally, amodified Dulbecco's modified Eagle's medium was used. The medium had noanorganic salts (e.g. KCl, NaCl), amino acids (e.g. L-glutamin,L-prolin), vitamins (e.g. biotin, riboflavin, folic acid) or othersubstances (e.g. glucose, lipon acid, nucleotides).

Example 10 Induction of Metabolic Acidose

The following example describes the induction of a metabolic acidose(pH<7.2+/−0.1) in cultured RPE cells by changing the pH value. Like invivo, mammalia cell cultures need a pH optimum which is ranging from pH7,2-7,4. Growing cells will cause a decrease of the pH-value due tolactate production. The pH value of the medium is measured in a bloodgas analyzer (Corning model 178). Two ways were used to induce ametabolic acidose: Changing the CO₂ pressure (from 5% to 0%) incombination with leaking HCO₃ in the culture medium (Palmer et al.,1998) (Palmer L A, Semenza G L, Stoler M H, Johns R A.: Hypoxia inducestype II NOS gene expression in pulmonary artery endothelial cells viaHIF-1. Am J. Physiol. 1998 February;274(2 Pt 1):L212-9) and the use of amodified Dulbecco's modified Eagle's medium containing 20 mM Hepesbuffer. A Hepes buffer medium can be used for pH stress of cells becausea medium buffered with Hepes is acidified in a humidified atmospherecontaining 5% CO₂ at 37° C.

Example 11 RNA-Preparation from Cultured Primary RPE Cells

RNA prepared from primary RPE cells served as starting material forexpression analyses for both real-time PCR and DNA-microarrays. Afterstress exposition (like hypoxic culture conditions, nutrient and/orgrowth factor deficiencies or pH changes) RPE cells were washed oncewith PBS prior to cell lysis. Approximately 1×10⁶ cells (e.g. one wellof a six well cell culture plate) were lyzed with 800 μl ofβ-mercaptoethanol containing RLT buffer (RNeasy Mini Kit from QiagenGermany) by softly shaking the plate. Lysates were immediately frozen at−80° C. After thawing for 15 min at 37° C. lysates were processed forisolation of total RNA according to the manufacturer's protocol (RNeasyMini Kit, Qiagen). The RNA on the matrix of one column (according to1×10⁶ cells) was eluted with with a suitable volume (10-100 μl) RNasefree water. RNA from identically cultivated cells was pooled to yielduniform RNA from one culture condition.

Example 12 DNase I Digestion of Contaminating Genomic DNA

For subsequent analysis of RNA care should be taken to eliminatecontaminating genomic DNA. Therefore digestion of genomic DNA viaenzymatic restriction with DNA polymerase I (RNase free DNase I) was beperformed. In brief a 100 μl reaction volume contained up to 50 μg RNAtogether with 20 μl of 25 mM MgSO₄ (final conc. 5 mM), 3.4 μl 3M NaAc pH4.7 (final conc. 100 mM) and 20 U DNase I (2 μl of 10 U/μl stock e.g.from Roche Diagnostics). Digestion was performed for 1 h at 37° C.Subsequent purification of RNA from DNAse and restricted DNA fragmentswas carried out again by utilizing the RNeasy Mini Kit (Qiagen)according to the supplier's recommendations.

Example 13 cDNA Synthesis for Expression Analysis via Real-Time PCR

Synthesis of cDNA from total RNA is a prerequisite for expressionanalyses both by real-time PCR and microarray technique. To allowcomparison of gene expression between mRNAs derived from differentculture conditions the same amount of total RNA (here: e.g. 2 μg perdifferent RNA) was reversely transcribed to cDNA by the following: 1 μloligo-dT-primer (500 μg/ml, Qiagen-Operon, # 55000142), 2 μg RNA fromporcine RPE cells, 1 μl 10 mM dNTP-mix (Invitrogen) and RNAse-free water(Qiagen) up to 12 μl in total. The mixture was incubated at 65° C. for 5min followed by 2 min on ice. After brief centrifugation following kitcomponents (Invitrogen, # 18064-014) were added: 4 μl 5× First Strandbuffer, 2 μl 0,1 M DTT and 1 μl RNasin (40 U/μl, Promega, # N2511).After mixing by pipetting up and down the reaction was incubated for 2min at 42° C. in a water bath. Then 1 μl reverse transcriptase(Superscript II, Invitrogen kit see above) was added and mixed bypipetting up and down. The reaction was incubated for 50 min at 42° C.in water bath and subsequently stopped by switching the reaction tubefor 15 min to a 70° C. heat block. After short incubation on ice thenewly synthesized cDNA was centrifuged and stored at −20° C. until use.

Example 14 Real-Time PCR

Concentrations of cDNA used as template in real-time PCR varied between100 pg and 100 ng (refering to the original RNA). For each gene ofinterest and control genes specific TaqMan™ probes (containing afluorescent dye and a quencher molecule) can be designed. Alternatively,the dye SYB®-Green can be used, which intercalates in all doublestranded DNA molecules, allowing the in process measurement of arisingPCR products. Oligonucleotides for PCR amplification (in real-time PCRand microarray analysis) were designed to achieve PCR fragments ofusually 150-600 base pairs (bp) in size. Along with the gene(s) ofinterest PCR probes were set up in duplicate or triplicate together withcontrol or housekeeping genes like beta-actin (ACTB), glyceraldehyde3-phosphate dehydrogenase (GAPD) or hypoxanthinephosphoribosyltransferase (HPRT1). A typical 25 μl PCR reaction wascomposed like the following: Template cDNA (100 pg-100 ng), HotStartTaq-polymerase (e.g. Invitrogen) 0.5 U/μl, 1× polymerase reactionbuffer, 0.2 mM of each dNTP (e.g. Invitrogen), 1.5 to 7 mM MgCl₂ (e.g.Invitrogen), oligonucleotides in the range between 50-300 nM (e.g.Qiagen-Operon, Germany) and SYBR®-Green (e.g. Bio Whittaker MolecularApplications, # 50512, 10,000× conc.) 0.1-0.5× (diluted from stock).Typical PCR conditions for real-time PCR were: 5-15 min activation stepat 95° C., 45 cycles with each 30 s denaturation at 94° C., annealing ofprimers (temperature depending on melting temperature of primers) for 30s and elongation of primers at 72° C. for up to 1 min. After each cyclethe increase in fluorescence of the probe during PCR amplification wasdetermined by the optical unit of the real-time PCR device (e.g. icyclerfrom BIORAD). The data from real-time PCR generated from control versustreated sample gave a profound information about changes in mRNAexpression.

Example 15 PCR Amplification of Target Genes for Spotting on MicroarraySlides

From all selected target genes PCR fragments of 150-600 bp wereamplified from RPE-/retina- or liver-specific cDNA (as templates)according to the following protocol: PCR reactions were typically set upin a total of 50 μl. They usually contained 1× polymerase reactionbuffer (e.g. Invitrogen), 1.5-4 mM (final concentration) MgCl₂ (e.g.Invitrogen), 0.2 mM of each nucleotide (10 mM dNTP stock, e.g.Invitrogen), up to 1 μM of gene specific forward and reverse primer(Qiagen Operon), 0.025-1 U Taq polymerase (e.g. Invitrogen), a suitableamount of template cDNA (1-10 μl, depending on cDNA quality) andnuclease free water to a final volume of 50 μl. Typical conditions forPCR were: a single 5 min denaturation step at 95° C., 30 cycles witheach 30 s denaturation at 94° C., annealing of primers (usually between45°-65° C., temperature depending on melting temperature of primers) for30 s and elongation of primers at 72° C. for up to 1 min.

Example 16 PCR Purification

PCR purification was performed by utilizing the QiaQuick PurificationKit (Qiagen) according to the manufacturer's recommendations.

Example 17 Spotting of PCR-Products on Coated Glass-Slides

DNA from PCR products was arrayed with splitted pins (Telechem) on CMTGAPS coated slides (Corning) with a Genepak spotter (Genetix) using 50%DMSO as spotting buffer. Spotted slides were stored for up to 6 months.

Example 18 Labeling of RNAs for Hybridization

For each labeling reaction 5 μg of RNA (at least 300 ng/μl, OD_(260/280)between 1.8 and 2.0) are recommended. Direct labeling of control RNA(from control/untreated cells) and test RNA (from stressed/treatedcells) with Cy3 and Cy5 (supplied from Amersham Biosciences or PerkinElmer) was done with the Qiagen kit ‘Label Star’ according to thesupplier's protocol.

Example 19 Hybridization of RNAs with Microarray

Hybridization of mixed RNAs with the spotted DNA on the microarrays wasperformed at 42° C. overnight on a automated Lucidea Slideprohybridization station (Amersham Biosciences) under well definedhybridization and washing conditions: Hybridization buffer was composedof 25% formamide, 5×SSC und 0.1% SDS.

Example 20 Image Processing and Data Analysis of Arrays

After hybridization the signals on the microarrays were scanned with alaser scanner. (ScanArray 4000, Perkin Elmer) to yield the raw imagedata. To extract the signal information from above generated images intotab delimited text files software tools like ScanAlyze (Mike Eisen,Stanford University, CA., http://rana.lbl.gov/EisenSoftware.htm) wereapplied. Normalization of data was done by applying Microsoft's Exceland Access programs (part of Microsoft Office packages). Such prepareddata were analyzed with software programs like GeneSpring from SiliconGenetics, which enable e.g. complex cluster analysis to finddifferentially expressed genes.

Example 21 Inhibition of the Expression of Green Fluorescent Protein(eGFP) in the Retinal Pigment Epithelium (RPE) and the Retina ofTransgenic Mice by dsRNA Molecules

This example describes specific post transcriptional gene silencing bydsRNA of the target gene eGFP in the mouse animal model, during whichthe optimal dsRNA concentration for post transcriptional gene silencingon systemic application is to be determined (experimental procedure 1,results see FIG. 1). The procedure involves the in vivo treatment oftransgenic mice (FVB.Cg-Tg(GFPU)5Nagy, The Jackson Laboratory), whichexpress the enhanced form of green fluorescent protein (eGFP) in theirbody cells, by systemic application of dsRNA oligoribonucleotidemolecules against the target gene eGFP. Control animals are also treatedsystemically with non-silencing dsRNA molecules. For the purpose of posttranscriptional gene silencing, the animals not under analgesic oranesthetic influence receive daily i.v. tail vein injections (1^(st) dayof treatment: day 0, final day of treatment: day 20) of 100 or 200 μgeGFP-specific dsRNA/kg body weight (BW) and the control group of 200 μgnon-silencing dsRNA/kg BW. A control group of animals treated withbuffer (daily i.v. injection of 0.1 ml buffer into the tail vein) isalso kept. Each group of experimental animals consists of 8 animals, themaximum injection volume/injection being 0.1 ml. On day 21, the animalsare sacrificed by CO₂ inhalation.

The expression of green fluorescent protein in the eye of the mice isexamined immunohistologically (spontaneous eGFP fluorescence:fluorescence microscopic evaluation; eGFP-specific immunofluorescencestaining: fluorescence microscopic evaluation).

dsRNA Constructs and Plasmids:

For the design of the dsRNA molecules, sequences of the type AA(N19)TT(where N represents any nucleotide) were selected from the sequence ofthe target mRNA, in order to obtain 21 nucleotide (nt) long sense andantisense strands with symmetrical 3′-overhangs of two nucleotides inlength. In the 3′-overhangs, 2′-deoxy-thymidine was used instead ofuridine. In order to ensure that the dsRNA molecules are exclusivelydirected against the target gene, the chosen dsRNA sequences are testedagainst the mouse genome in a BLAST analysis. The 21-nt RNA moleculesare synthesized chemically and purified. For the duplex formation, 100μg of the sense and antisense oligoribonucleotides each are mixed in 10mM Tris/HCl, 20 mM NaCl (pH 7.0) and heated to 95° C. and cooled to roomtemperature over a period of 18 hours. The dsRNA molecules areprecipitated from ethanol and resuspended in sterile buffer (100 mMpotassium acetate, 30 mM HEPES-KOH, 2 mM magnesium acetate, pH 7.4). Theintegrity and double strand character of the dsRNA are verified bygelelectrophoresis. Alternatively, the dsRNA molecules are obtained fromcommercial suppliers. The sequences of the target genes and thecorresponding dsRNA molecules are as follows: DNA target sequence: 5′GCAA GCT GAC CCT GAA GTT CA (SEQ ID NO 5) Coding region, 121-141 relativeto the first nucleotide of the start codon (Acc. No. U55761) dsRNA(sense) 5′r(GCA AGC UGA CCC UGA AGU U) (SEQ ID NO 6) dsRNA (antisense)5′r(AA CUU CAG GGU CAG CUU GC) (SEQ ID NO 7)

Non-Silencing dsRNA, Control DNA target sequence:5′AATTCTCCGAACGTGTCACGT (SEQ ID NO 8) dsRNA (sense)5′r(UUCUCCGAACGUGUCACGU)d(TT) (SEQ ID NO 9) dsRNA (antisense)5′r(ACGUGACACGUUCGGAGAA)d(TT) (SEQ ID NO 10)Analgesia and Anesthesia of the Mice:

For systemic application, the animals are immobilized and the dsRNAs areinjected i.v. in the tail vein (maximal injection volume: 0.1 ml), whereanalgesia or anesthesia are refrained from, since this would put morestress on the animals than the i.v. injection itself. For retrobulbarinjection (maximal injection volume: 0.005 ml) the animals are howeversubjected to short-term isofluorane inhalation anaesthesia and providedwith Metamizole sodium for analgesic purposes. The animals are then keptin their accustomed animal cage surroundings. After completion of invivo diagnosis (the end of each animal experiment is stated respectivelyin example 1-5) the animals are killed by CO₂ inhalation, enucleated andthe eyes are studied histologically (immunohistology).

Study of eGFP Expression in Retinal Pigment Epithelium and Retina:

After removal, the eyes are fixed in 4% formalin/PBS solution for 24hours. Using standard methods, the fixed samples are subsequentlydehydrated in a series of increasing alcohol and embedded in paraffin.With the aid of a microtome, standard 5 to 12 μm serial slices areproduced, stretched in a heated water bath and transferred to apolylysin-coated cover slip. The sections are then dried in an incubatorfor 2 hours at a temperature of 52° C. The dried sections aredeparaffinated in xylol, transferred to a decreasing series of alcoholfollowed by Tris/HCl pH 7.4. After blocking, the sections are incubatedfor 2 hours with primary anti-eGFP antiserum (polyclonal goat anti-eGFPantiserum, Santa Cruz No. sc-5384). Detection occurs by means ofimmunofluorescence staining by using a Cy2-conjugated rabbit anti-goatIgG (Dianova, No. 305-225-045). The samples are embedded and thenmounted for microscopy with an Eclipse TE-2000-S microscope (Nikon),equipped with a 20× and 40×/1.3 objective. The spontaneous,eGFP-specific fluorescence in deparaffinated, untreated sections isanalyzed using a fluorescence microscope.

Experimental procedure: Systemic siRNA application. Determination ofoptimal dsRNA concentration for post transcriptional gene silencing.Group Substance Number of animals Control animals Buffer 8 Negativecontrol non- silencing dsRNA 8 200 μg dsRNA/kg BW 200 μg dsRNA/kgeGFP-specific dsRNA 8 BW 100 μg dsRNA/kg eGFP-specific dsRNA 8 BWAnimals per 32  experiment

For results see FIG. 1 Accession Alternative Genname No marker for CDSDescription Symbols Citation BAX NM_138761 apoptosis  53 . . . 631BCL2-associated X protein unknown Martindale et al. (BAX), transcriptvariant alpha J Cell Physiol. 2002 Jul; 192(1): 1-15. BBC3 NM_014417apoptosis   1 . . . 582 BCL2 binding component 3 JFY1, PUMA, Martindaleet al. (BBC3) PUMA/JFY1 J Cell Physiol. 2002 Jul; 192(1): 1-15. BCL2NM_000633 apoptosis  32 . . . 751 B-cell CLL/lymphoma 2 unknownNicotera. (BCL2), transcript variant alpha Toxicol Lett. 2002 Feb 28;127(1-3): 189-95. BIRC2 NM_001166 apoptosis 1160 . . . 3016 baculoviralIAP repeat- API1, MIHB, CIAP1, Martindale et al. containing 2 (BIRC2)HIAP2 J Cell Physiol. 2002 Jul; 192(1): 1-15. BIRC3 NM_001165 apoptosis 725 . . . 2539 baculoviral IAP repeat- AP12, MIHC, CIAP2, Martindale etal. containing 3 (BIRC3) HAIP1, HIAP1 J Cell Physiol. 2002 Jul; 192(1):1-15. BIRC4 NM_001167 apoptosis  34 . . . 1527 baculoviral IAP repeat-ILP, API3, ILP1, Martindale et al. containing 4 (BIRC4) MIHA, XIAP,Xiap, J Cell Physiol. 2002 hILP, ILP-1 Jul; 192(1): 1-15. CDKN1ANM_078467 apoptosis  236 . . . 730 cyclin-dependent kinase P21, CIP1,SDI1, Almond & Cohen. inhibitor 1A (p21, WAF1, CAP20, Leukemia. 2002Apr; Cip1) (CDKN1A), transcript CDKN1, MDA-6 16(4): 433-43. variant 2ENDOG NM_004435 apoptosis  167 . . . 1060 endonuclease G (ENDOG) unknownAlmond & Cohen. Leukemia. 2002 Apr; 16(4): 433-43. HSPD1 NM_002156apoptosis  25 . . . 1746 heat shock 60 kDa protein 1 GROEL, HSP60,Martindale et al. (chaperonin) (HSPD1) SPG13 J Cell Physiol. 2002 Jul;192(1): 1-15. HSPE1 NM_002157 apoptosis  42 . . . 350 heat shock 10 kDaprotein 1 CPN10, GROES, Ravagnan et al. (chaperonin 10) (HSPE1) HSP10 JCell Physiol. 2002 Aug; 192(2): 131-7. LRDD NM_145886 apoptosis  144 . .. 2876 leucine-rich and death PIDD, MGC16925 Martindale et al. domaincontaining (LRDD), J Cell Physiol. 2002 transcript variant 1 Jul;192(1): 1-15. MCL1 NM_021960 apoptosis  64 . . . 1116 myeloid cellleukemia EAT Bae et al. J. sequence 1 (BCL2- Biol. Chem. 275: related)(MCL1) 25255-25261, 2000. P53AIP1 AB045830 apoptosis  211 . . . 585 forp53AIP1, complete cds unknown Martindale et al. J Cell Physiol. 2002Jul; 192(1): 1-15. PMAIP1 NM_021127 apoptosis  174 . . . 338phorbol-12-myristate-13- APR, NOXA Martindale et al. acetate-inducedprotein 1 J Cell Physiol. 2002 (PMAIP1) Jul; 192(1): 1-15. TNFRSF10BNM_147187 apoptosis  286 . . . 1521 tumor necrosis factor DR5, KILLER,Martindale et al. receptor superfamily, TRICK2, TRICKB, J Cell Physiol.2002 member 10b ZTNFR9, TRAILR2, Jul; 192(1): (TNFRSF10B), transcriptTRICK2A, TRICK2B, 1-15. variant 2 TRAIL-R2, KILLER/DR5 TNFRSF6 NM_000043apoptosis  347 . . . 1354 tumor necrosis factor FAS, APT1, CD95, Hueber.Nature Cell receptor superfamily, APO-1, FASTM Biol. 2: member 6(TNFRSF6), E23-E25, 2000. transcript variant 1,. TOP2B NM_001068apoptosis   1 . . . 4866 topoisomerase (DNA) II TOPIIB Solovyan et al.beta 180 kDa (TOP2B) J Biol Chem. 2002 Jun 14; 277(24): 21458-67. TP53NM_000546 apoptosis  252 . . . 1433 tumor protein p53 (Li- P53, p53,TRP53 Almond & Cohen. Fraumeni syndrome) Leukemia. 2002 (TP53), Apr;16(4): 433-43. EPO NM_000799 hypoxic cult.cond  182 . . . 763erythropoietin (EPO),. EP Grimm et al. Nature Med. 8: 718-724, 2002.FGF2 NM_002006 hypoxic cult.cond  302 . . . 934 fibroblast growth factor2 BFGF, FGFB, HBGH-2 Grimm et al. (basic) (FGF2), Nature Med. 8:718-724, 2002. LDHA NM_005566 hypoxic cult.cond  98 . . . 1096 lactatedehydrogenase A unknown Semenza et al. J Biol Chem. 1996 Dec 20;271(51):32529-37. NGB NM_021257 hypoxic cult.cond  376 . . . 831 neuroglobin(NGB),. unknown Burmester et al. Nature 407 (6803), 520-523 (2000) VEGFNM_003376 hypoxic cult.cond  702 . . . 1277 vascular endothelial growthVEGFA Grimm et al. factor (VEGF), Nature Med. 8: 718-724, 2002. AVENNM_020371 oxidative stress  53 . . . 1141 apoptosis, caspase PDCD12Martindale et al. activation inhibitor (AVEN),. J Cell Physiol. 2002Jul; 192(1): 1-15. BCL2A1 NM_004049 oxidative stress  184 . . . 711BCL2-related protein A1 GRS, BFL1, HBPA1, Martindale et al. (BCL2A1),.BCL2L5 J Cell Physiol. 2002 Jul; 192(1): 1-15. CAT NM_001752 oxidativestress  69 . . . 1652 catalase (CAT), unknown Cai et al. Prog Retin EyeRes. 2000 Mar; 19(2): 205-21. DUSP1 NM_004417 oxidative stress  249 . .. 1352 dual specificity HVH1, CL100, MKP-1, Wu et al. phosphatase 1(DUSP1),. PTPN10 J Biol Chem. 2002 Nov 15; 277(46): 44208-13. GADD45NM_001924 oxidative stress  296 . . . 793 growth arrest and DNA- DDIT1,GADD45 Martindale et al. damage-inducible, alpha J Cell Physiol. 2002(GADD45A),. Jul; 192(1): 1-15. HMOX1 NM_002133 oxidative stress  81 . .. 947 heme oxygenase HO-1, bK286B10 Martindale et al. (decycling) 1(HMOX1), J Cell Physiol. 2002 Jul; 192(1): 1-15. IL6 NM_000600 oxidativestress  63 . . . 701 interleukin 6 (interferon, HGF, HSF, BSF2, IL-6,Martindale et al. beta 2) (IL6) IFNB2 J Cell Physiol. 2002 Jul; 192(1):1-15. MAP2K6 NM_002758 oxidative stress  341 . . . 1345mitogen-activated protein MEK6, MKK6, Seger & Krebs. kinase kinase 6(MAP2K6), MAPKK6, PRKMK6, FASEB J. 9: transcript variant 1 SAPKK3726-735, 1995. MAPK8 NM_139049 oxidative stress  18 . . . 1301mitogen-activated protein JNK, JNK1, PRKM8, Almond & Cohen. kinase 8(MAPK8), SAPK1, JNK1A2, Leukemia. 2002 Apr; transcript variant 1JNK21B1/2 16(4): 433-43. MAPK9 NM_002752 oxidative stress  50 . . . 1324mitogen-activated protein JNK2, JNK2A, Martindale et al. kinase 9(MAPK9), JNK2B, PRKM9, JNK-55, J Cell Physiol. 2002 transcript variant 1JNK2BETA, Jul; 192(1): P54ASAPK, 1-15. p54aSAPK, JNK2ALPHA NFKB2NM_002502 oxidative stress  164 . . . 2965 nuclear factor of kappaLYT10, LYT-10 Martindale et al. light polypeptide gene J Cell Physiol.2002 enhancer in B-cells 2 Jul; 192(1): (p49/p100) (NFKB2), 1-15. PRDX2NM_005809 oxidative stress  90 . . . 686 peroxiredoxin 2 (PRDX2),. PRP,TSA, NKEFB, Fujii & Ikeda. TDPX1 Redox Rep. 2002; 7(3): 123-30. Review.SFN NM_006142 oxidative stress  166 . . . 912 stratifin (SFN), unknownMartindale et al. J Cell Physiol. 2002 Jul; 192(1): 1-15. SHC1 NM_003029oxidative stress  195 . . . 1946 SHC (Src homology 2 SHC, SHCAMartindale et al. domain containing) J Cell Physiol. 2002 transformingprotein 1 (SHC1), Jul; 192(1): 1-15. SOD1 NM_000454 oxidative stress   1. . . 465 superoxide dismutase 1, ALS, ALS1, IPOA Martindale et al.soluble (amyotrophic lateral J Cell Physiol. 2002 sclerosis 1 (adult))(SOD1), Jul; 192(1): 1-15. SOD2 NM_000636 oxidative stress   5 . . . 673superoxide dismutase 2, IPO-B, MNSOD Martindale et al. mitochondrial(SOD2), J Cell Physiol. 2002 Jul; 192(1): 1-15. TNFAIP3 NM_006290oxidative stress  67 . . . 2439 tumor necrosis factor, A20, TNFA1P2Martindale et al. alpha-induced protein 3 J Cell Physiol. 2002(TNFAIP3), Jul; 192(1): 1-15. TRAF1 NM_005658 oxidative stress  79 . . .1329 TNF receptor-associated EBI6, MGC:10353 Martindale et al. factor 1(TRAF1), J Cell Physiol. 2002 Jul; 192(1): 1-15. TRAF2 NM_021138oxidative stress  58 . . . 1563 TNF receptor-associated TRAP, TRAP3,Martindale et al. factor 2 (TRAF2), transcript MGC:45012 J Cell Physiol.2002 variant 1, Jul; 192(1): 1-15.

REFERENCES

-   Banks C N, Hutton W K. Blindness in New South Wales: an estimate of    the prevalence and some of the contributing causes. Aust J    Ophthalmol 9:285-288 (1981).-   Bohler C, Nielsen P E, Orgel L E. Template switching between PNA and    RNA oligonucleotides. Nature. 376(6541):578-81 (1995).-   Bernstein E, Caudy A A, Hammond S M, Hannon G J. Role for a    bidentate ribonuclease in the initiation step of RNA interference.    Nature 409(6818):363-6 (2001).-   Bressler N M. Early detection and treatment of neovascular    age-related macular degeneration.) J Am Board Fam Pract. 15:142-152    (2002).-   Bressler N M, Bressler S B. Preventative ophthalmology. Age-related    macular degeneration. Ophthalmology 102:1206-1211 (1995).-   Bressler N M, Bressler S B, Fine S L. Age-related macular    degeneration. Surv Ophthalmol 32:375-413 (1988).-   Bressler S B, Bressler N M, Fine S L, Hillis A, Murphy R P, Olk R J,    Patz A. Natural course of choroidal neovascular membranes within the    foveal avascular zone in senile macular degeneration. Am J    Ophthalmol 93:157-163 (1982).-   Campochiaro P A, Soloway P, Ryan S J, Miller J W. The pathogenesis    of choroidal neovascularization in patients with age-related macular    degeneration. Mol Vis. 5:34 (1999).-   Caplen N. J., Parrish S., Imani F., Fire A., and Morgan R. A.    Specific inhibition og gene expression by small double-stranded RNAs    in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci.    09:9742-9747 (2001).-   Davis L G, Kuehl M, Kuehl M W, Battey J F. Basic methods in    molecular biology. Sec. Ed. Elsevier (1990).-   Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., and    Tuschel T. Duplexes of 21-nucleotide RNAs mediate RNA interference    in cultured mammalian cells. Nature 411: 494-498 (2001).-   Feeney L. Lipofuscin and melanin of human retinal pigment    epithelium. Fluorescence, enzyme cytochemical, and ultrastructural    studies. Invest Ophthalmol Vis Sci 17:583-600 (1978).-   Feeney-Burns L, Ellersieck M R. Age-related changes in the    ultrastructure of Bruch's membrane. Am J Ophthalmol    100:686-697(1985).-   Finn P J, Gibson N J, Fallon R, Hamilton A, Brown T. Synthesis and    properties of DNA-PNA chimeric oligomers. Nucleic Acids Res. 24:    3357-3363 (1996).-   Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., and    Mello C. C. Potent and specific genetic interference by    double-stranded RNA in Coenorhabditis elegans. Nature    391:806-811(1998).-   Fischer S G, Lerman L S. DNA fragments differing by single base-pair    substitutions are separated in denaturing gradient gels:    correspondence with melting theory. Proc Natl Acad Sci USA.    80(6):1579-83 (1983).-   Gass J D. Drusen and disciform macular detachment and degeneration.    Arch Ophthalmol 90:206-217 (1973).-   Gass J D. Pathogenesis of disciform detachment of the    neuroepithelium. Am J Ophthalnol 63: Suppl:1-139(1967).-   Ghafour I M, Allan D, Foulds W S. Common causes of blindness and    visual handicap in the west of Scotland. Br J Ophthalmol 67: 209-213    (1983).-   Gossen M, Bonin A L, Freundlieb S, Bujard H. Inducible gene    expression systems for higher eukaryotic cells. Curr Opin    Biotechnol. 5(5):516-20 (1994).-   Gossen M, Bujard H. Tight control of gene expression in mammalian    cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA.    89(12):5547-5551 (1992).-   Gotoh M, Hasebe M, Ohira T, Tosu M. [Gene diagnosis with an affinity    sensor, BIACORE—principle and applications]. Rinsho Byori.    45(3):224-8 (1997). Japanese.-   Green W R, McDonnell P J, Yeo J H. Pathologic features of senile    macular degeneration. Ophthalmology 92:615-27 (1985).-   Grey R H, Burns-Cox C J, Hughes A. Blind and partial sight    registration in Avon. Br J Ophthalmol 73:88-94(1989).-   Grishok A, Pasquinelli A E, Conte D, Li N, Parrish S, Ha I, Baillie    D L, Fire A, Ruvkun G, Mello C C. Genes and mechanisms related to    RNA interference regulate expression of the small temporal RNAs that    control C. elegans developmental timing. Cell 106(1):23-34 (2001).-   Hamilton A J and Baulcombe D C. A species of small antisense RNA in    posttranscriptional gene silencing in plants. Science 286:    950-952(1999).-   Heiba I M, Elston R C, Klein B E, Klein R. Sibling correlations and    segregation analysis of age-related maculopathy: the Beaver Dam Eye    Study. Genet Epidemiol 11:51-67 (1994).-   Hogan M J, Alvarado J. Studies on the human macula. IV. Aging    changes in Bruch's membrane. Arch Ophthalmol 77:410-420(1967).-   Hyman L G, Lilienfeld A M, Ferris F L, Fine S L. Senile macular    degeneration: a case-control study. Am J Epidemiol 118:213-227    (1983).-   Hyman L. Epidemiology of eye disease in the elderly. Eye 1: 330-341    (1987).-   Jalkanen M, Nguyen H, Rapraeger A, Kurn N, Bernfield M. Heparan    sulfate proteoglycans from mouse mammary epithelial cells:    localization on the cell surface with a monoclonal antibody. J. Cell    Biol. 101(3):976-984 (1985).-   Jalkanen M, Rapraeger A, Saunders S, Bernfield M. Cell surface    proteoglycan of mouse mammary epithelial cells is shed by cleavage    of its matrix-binding ectodomain from its membrane-associated    domain. J. Cell Biol. 105:3087-96 (1987).-   Jensen K K, Orum H, Nielsen P E, Norden B. Kinetics for    hybridization of peptide nucleic acids (PNA) with DNA and RNA    studied with the BIAcore technique. Biochemistry 36(16):5072-5077    (1997).-   Joyner A. Gene Targeting, A Practical Approach, Second edition,    Oxford University Press (1999).-   Kasschau K D and Carrington J C. A counterdefensive strategy of    plant viruses: suppression of posttranscriptional gene silencing.    Cell 95:461-470(1998).-   Klein R, Klein B E, Franke T. The relationship of cardiovascular    disease and its risk factors to age-related maculopathy. The Beaver    Dam Eye Study. Ophthalmology 100:406-414 (1993).-   Knight S W and Bass B L. A role for the RNase III enzyme DCR-1 in    RNA interference and germ line development in Caenorhabditis    elegans. Science 2: 2269-2271(2001).-   Koch T, Hansen H F, Andersen P, Larsen T, Batz H G, Otteson K,    Orum H. Improvements in automated PNA synthesis using Boc/Z    monomers. J Pept Res. 49(1):80-8 (1997).-   Köhler G, Milstein C. Continuous cultures of fused cells secreting    antibody of predefined specificity. Nature 256(5517):495-497 (1975).-   Leibowitz H M, Krueger D E, Maunder L R, Milton R C, Kini M M, Kahn    H A, Nickerson R J, Pool J, Colton T L, Ganley J P, Loewenstein J I,    Dawber T R. The Framingham Eye Study monograph: An ophthalmological    and epidemiological study of cataract, glaucoma, diabetic    retinopathy, macular degeneration, and visual acuity in a general    population of 2631 adults, 1973-1975. Surv Ophthalmol 24(Suppl):    335-610 (1980).-   Le Mouellic H, Lallemand Y, Brulet P. Targeted replacement of the    homeobox gene Hox-3.1 by the Escherichia coli lacZ in mouse chimeric    embryos. Proc Natl Acad Sci USA. 87(12):4712-4716 (1990).-   Maguire P, Vine A K. Geographic atrophy of the retinal pigment    epithelium. Am J Ophthalmol 102:621-625 (1986).-   Mantero G, Zonaro A, Albertini A, Bertolo P, Primi D. DNA enzyme    immunoassay: general method for detecting products of polymerase    chain reaction. Clin Chem. 37(3):422-429 (1991).-   Mayer R J, Walker J H, eds. Immunochemical methods in cell and    molecular biology. Academic Press, London (1987).-   Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo M P.    Inhibition of proliferation by c-myb antisense oligodeoxynucleotides    in colon adenocarcinoma cell lines that express c-myb. Cancer Res.    51:2897-2901 (1991)-   Meyers S M, Zachary A A. Monozygotic twins with age-related macular    degeneration. Arch Ophthalnol 106:651-653 (1988).-   Paetkau M E, Boyd T A, Grace M, Bach-Mills J, Winship B. Senile    disciform macular degeneration and smoking. Can J Ophthalmol    13:67-71 (1978).-   Pauleikhoff D, Harper C A, Marshall J, Bird A C. Aging changes in    Bruch's membrane. A histochemical and morphologic study.    Ophthalmology 97:171-178(1990).-   Piguet B, Wells J A, Palmvang I B, Wormald R, Chisholm I H, Bird    A C. Age-related Bruch's membrane change: a clinical study of the    relative role of heredity and environment. Br J Ophthalmol    77:400-403 (1993).-   Sambrook et al., Molecular Cloning, A Laboratory Manual, 2^(nd)    edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring    Harbor, N.Y.-   Sarks S H. Ageing and degeneration in the macular region: a    clinico-pathological study. Br J Ophthalmol 60:324-341 (1976).-   Schuler G D. Pieces of the puzzle: expressed sequence tags and the    catalog of human genes. J Mol Med. 75(10):694-8 (1997)-   Seddon J M, Ajani U A, Mitchel B D. Fainilial aggregation of    age-related maculopathy. Am J Ophthalmol 123: 199-206 (1997).-   Smith and Johnson. Single-step purification of polypeptides    expressed in Escherichia coli as fusions with glutathione    S-transferase. Gene 67:3140 (1988)-   Silvestri G, Johnston P B, Hughes A E. Is genetic predisposition an    important risk factor in age-related macular degeneration? Eye    8:564-568 (1994).-   Sobol R E, Astarita R W, Chisari F V, Griffiths J C, Royston I. Use    of immunoglobulin light chain analysis to detect bone marrow    involvement in B-cell neoplasms. Clin Immunol Immunopathol.    24(1):139-144 (1982).-   Sobol R E, Dillman R O, Collins H, Griffiths J C, Green M R,    Royston I. Applications and limitations of peripheral blood    lymphocyte immunoglobulin light chain analysis in the evaluation of    non-Hodgkin's lymphoma. Cancer 56(8):2005-2010 (1985).-   Sperduto R D, Hiller R. Systemic hypertension and age-related    maculopathy in the Framingham Study. Arch Ophthalmol 104:216-219    (1986).-   Steinecke, Ribozymes, Methods in Cell Biology 50, Galbraith et al.    eds Academic Press, Inc.: 449-460 (1995).-   The Eye Disease Case-Control Study Group. Risk factors for    neovascular age-related macular. Arch Ophthalmol 110:1701-1708    (1992).-   Tijssen P.; Burden, R H and von Knippenburg (Eds). Practice and    theory of enzyme immuno-assays. Elsevier, Amsterdam, Vol. 15 (1985).-   Verma R. S.; Babu A. Human chromosomes; Manual of basic techniques.    New York, Pergamon Press (1989).-   Veselkov A G, Demidov V V, Frank-Kamenetskii M, Nielsen P E. PNA as    a rare genome-cutter. Nature. 379(6562):214 (1996).-   Wahl R L, Parker C W, Philpott G W. Improved radioimaging and tumor    localization with monoclonal F(ab′)2. J Nucl Med. 24(4):316-25    (1983).-   Weiler J, Gausepohl H, Hauser N, Jensen O N, Hoheisel J D.    Hybridisation based DNA screening on peptide nucleic acid (PNA)    oligomer arrays. Nucleic Acids Res. 25(14):2792-9 (1997).-   Yap M, Weatherill J. Causes of blindness and partial sight in the    Bradford Metropolitan District from 1980 to 1985. Ophthalmic Physiol    Opt 9:289-292 (1989).-   Yuzawa M, Isomae T, Mori R, Shimada H, Utsunomiya I. Surgical    excision versus laser photocoagulation for subfoveal choroidal    neovascular membrane with age-related macular degeneration:    comparison of visual outcomes. Jpn J Ophthalmol. 45(2):192-8 (2001).-   Zamore P D, Tuschl T, Sharp P A, Bartel D P. RNAi: double-stranded    RNA directs the ATP-dependent cleavage of mRNA at 21 to 23    nucleotide intervals. Cell 101: 25-33(2000).

1. A method for the treatment of a disorder of the central nervoussystem (CNS) and/or the eye comprising administering to a subject acomposition comprising a compound capable of modulating a target gene orgene product in a therapeutically effective amount, wherein saidcomposition is administered outside the blood-brain and/or theblood-retina barriers.
 2. Use of a compound capable of modulating atarget gene or gene product for the preparation of a pharmaceuticalcomposition for the treatment of a disorder of the central nervoussystem (CNS) and/or the eye, wherein said composition is designed to beapplied outside the blood-brain and/or blood-retina barriers.
 3. Themethod of claim 1 or the use of claim 2, wherein the disorder is relatedto the eye.
 4. The method or use of any one of claims 1 to 3, whereinsaid disorder is related to angiogenesis and/or neovascularization. 5.The method or use of any one of claims 1 to 4, wherein said disorder isrelated to the retinal pigment epithelium (RPE), neurosensory retinaAND/OR choriodea.
 6. The method or use of any one of claims 1 to 5,wherein said disorder is wet age-related macular degeneration (AMD) ordiabetic retinopathy.
 7. The method or use of any one of claims 1 to 6,wherein the pharmaceutical composition is designated to be effective in(and applied to) the inner segment of the eye ball.
 8. The method or useof any one of claims 1 to 7, wherein the composition is in a formdesigned to be applied outside the retinal region of the blood-retinabarrier.
 9. The method or use of any one of claims 1 to 8, wherein saidcompound is an inhibitor/antagonist of said target gene or gene product.10. The method or use of claim 9, wherein said antagonist/inhibitorinhibits the expression of a gene or the activity of a gene productinvolved in angiogenesis and/or neovascularization.
 11. The method oruse of claim 9 or 10, wherein said antagonist/inhibitor is or is derivedfrom an nucleic acid molecule, polypeptide, antibody, or a ligandbinding molecule of said gene or gene product.
 12. The method or use ofany one of claims 9 to 11, wherein said antagonist/inhibitor is aribozyme, antisense or sense nucleic acid molecule to said gene or geneproduct.
 13. The method or use of any one of claims 9 to 12, whereinsaid antagonist/inhibitor substantially consists OF ribonucleotides. 14.The method or use of claim 13, wherein said antagonist/inhibitorcomprises substantially a portion of double-strandedoligoribonucleotides (dsRNA).
 15. The method or use of claim 14, whereinsaid dsRNA is between 21 and 23 nucleotides in length.
 16. The method oruse of claim 14 or 15, wherein the dsRNA molecule contains a terminal3′-hydroxyl group.
 17. The method or use of any one of claims 12 to 16,wherein the nucleic acid molecule represents an analogue of naturallyoccurring RNA.
 18. The method or use of claim 17, wherein the nucleotidesequence of the nucleic acid molecule differs from the nucleotidesequence of said gene or gene product by addition, deletion,substitution or modification of one or more nucleotides.
 19. The methodor use of any one of claims 10 to 18, wherein said gene or a cDNAthereof comprises a nucleotide sequence or encodes an amino acidsequence selected from the group consisting of any one of SEQ ID NOS: 1to
 4. 20. The method or use of any one of claims 1 to 19, wherein saidcompound is a nucleic acid molecule or encoded by a nucleic acidmolecule and is designed to be expressed in cells of the CNS or eye. 21.The method or use of any one of claims 1 to 20, wherein the compositionis in a form designed to be introduced into the cells or tissue of theCNS or eye by a suitable carrier, characterized by the applicationoccurring outside the blood-brain or blood-retina barriers.
 22. Themethod or use of any one of claims 1 to 21, wherein the composition isdesigned for systemic administration or for administration byiontophoresis.
 23. The method or use of any one of claims 1 to 21,wherein the composition is designed for retrobulbar application or aseye drops.
 24. A method of identifying and obtaining a nucleic acidmolecule encoding a polypeptide involved in a disorder as defined in anyone of claims 1 to 6 comprising the steps of: (a) culturing a cell,tissue or non-human animal under stress conditions which lead tosimulation of a pathological condition related to a CNS or eye disorder,(b) isolating nucleic acids AND/OR proteins from a sample of said cell,tissue or animal; (c) comparing the expression or activity profile of atleast one of said nucleic acids and/or proteins with that of acorresponding non-treated cell, tissue or animal, and/or with that of acell, tissue or animal, which has been treated under different stressconditions; (d) determining at least one nucleic acid and/or proteinwhich is differentially expressed, whereby a change of expression or ofthe active amount of said at least one nucleic acid or activity of atleast one of said proteins or an altered localization of the protein isindicative for its role in a disorder of the CNS or eye.
 25. The methodof claim 24, wherein said stress condition is generated by an aberrantsupply of the cell, tissue or animal culture conditions.
 26. The methodof claim 24 or 25 wherein said aberrant supply is an aberrant supply ofthe interior segment of the eye.
 27. The method of any one of claims 24to 26, wherein the method is a cell culture based method.
 28. The methodof claim 27, wherein said cell is an RPE cell.
 29. The method of claim28, wherein said cell is derived from an RPE derived cell line such ascell line ARPE-19.
 30. The method of any one of claims 24 to 26, whereinsaid method is performed with a non-human animal.
 31. The method of anyone of claims 24 to 30, wherein said stress conditions comprise e.g.oxidative stress, hypoxic culture conditions, insufficient nutritionand/or supply with growth factors, change of pH-value and/orpathophysiological concentration of rod outer segments (ROS) and/orA2-E.
 32. The method of any one of claims 24 to 31, wherein expressionof nucleic acids is analyzed with an expression array and/or realtimePCR.
 33. The method of any one of claims 24 to 32, wherein proteinexpression is analyzed with immunoblot or elisa assay, or 2D gelelectrophoresis or maldi-tof.
 34. The method of claim 33, whereinantibodies are used which are specific for proteins involved inangiogenesis and/or neovascularization.
 35. The method of any one ofclaims 24 to 34, further comprising overexpression or inhibition ofexpression of the identified candidate nucleic acid or encodedpolypeptide in said cell, tissue or animal for their capability ofinducing a responsive change in the phenotype of said cell, tissue oranimal, wherein said phenotype is related to a disorder of the CNS oreye.
 36. The method of any one of claims 24 to 35, further comprising:(e) subjecting a cell of step (a) or secreted factors thereof, or celllysates thereof, to endothelial cell cultures; and/or (f) analyzing cellproliferation, electrophysiological activity, DNA synthesis, out-growthof cells, cell migration, chemokinesis, chemotaxis, development ofvessels, marker gene expression or activity, apoptosis and/or vitality.37. The method of any one of claims 24 to 36, wherein a sample of saidcells are treated with an inhibitor specific for said candidate nucleicacid or encoded polypeptide; and further comprising determining whethersaid cells, secreted factors thereof or cell lysates thereof have losttheir capability of inducing said responsive change in said phenotype.38. The method of any one of claims 35 to 37, wherein said phenotype isangiogenesis and/or neovascularization and/or degenerative retinaldisorder.
 39. The method of claim 38, wherein said inhibitor is aninhibitor as defined in any one of claims 10 to
 19. 40. The method ofany one of claims 24 to 39, further comprising identifying the sequenceof said at least one nucleic acid and/or protein, and optionallyidentifying the corresponding encoding gene or cDNA thereof
 41. Themethod of claims 40, further comprising cloning said gene, cDNA or afragment thereof.
 42. A nucleic acid molecule obtainable by the methodof any one of claims 24 to
 41. 43. The nucleic acid molecule of claim 42encoding a polypeptide involved in angiogenesis and/orneovascularization and/or retinal disorder.
 44. A nucleic acid moleculewhich specifically hybridizes to the nucleic acid molecule of claim 42or 43, which encodes a mutated version of the protein which has lost itscapability of inducing a responsive change in a phenotype as defined inany one of claims 35 to
 38. 45. The nucleic acid molecule of any one ofclaims 42 to 44, which is DNA.
 46. (not entered)
 47. The nucleic acidmolecule of any one of claim 42 to 64, which is derived from a mammal.48. The nucleic acid molecule of claim 47, wherein the mammal is mouseor human.
 49. A nucleic acid molecule of at least 15 nucleotides inlength hybridizing specifically with a nucleic acid molecule of any oneof claims 42 to 48 or with a complementary strand thereof.
 50. A vectorcomprising a nucleic acid molecule of any one of claims 42 to
 49. 51.The vector of claim 50, wherein the nucleic acid molecule is operativelylinked to regulatory elements permitting expression in prokaryotic oreukaryotic host cells.
 52. A host cell comprising a vector of claim 50or
 51. 53. The host cell of claim 52, which is a bacterial, fungal,plant or animal cell.
 54. The host cell of claim 53, which is amammalian cell.
 55. The host cell of claim 54 which is an RPE cell or aneurosensory retina cell.
 56. A method for the production of apolypeptide capable of inducing a responsive change in a phenotype asdefined in any one of claims 35 to 38 comprising culturing a host cellof any one of claims 52 to 55 under conditions allowing the expressionof the polypeptide and re-covering the produced polypeptide from theculture.
 57. A polypeptide encoded by a nucleic acid molecule of any oneof claims 42 to 49 or obtainable by a method according to claim
 56. 58.An antibody specifically recognizing a polypeptide of claim
 57. 59. Apharmaceutical composition comprising a nucleic acid molecule of any oneof claims 42 to 49, or an nucleic acid molecule which is complementaryto such a nucleic acid molecule, a vector of claim 50 or 51, a host cellof any one of claims 52 to 55, a polypeptide of claim 57 and/or anantibody of claim 58, and optionally pharmaceutically acceptablecarrier.
 60. A diagnostic composition comprising a nucleic acid moleculeof any one of claims 42 to 49, a vector of claim 50 or 51, a host cellof any one of claims 52 to 55, a polypeptide of claim 57 and/or anantibody of claim 58, and optionally suitable means for detection.
 61. Amethod for treating of a disorder as defined in any one of claims 1 to 6comprising administering to the subject a pharmaceutical compositions ofclaim 59 in an effective dose.
 62. A method for detecting expression ofa gene involved in a disorder as defined in any one of claims 1 to 6comprising (a) obtaining mRNA from a cell; (b) incubating the MRNA soobtained with a probe comprising a nucleic acid molecule of any one ofclaims 42 to 49 or a fragment thereof under hybridizing conditions; and(c) detecting the presence of MRNA hybridized to the probe.
 63. A methodfor detecting expression of a gene involved in a disorder as defined inany one of claims 1 to 6 comprising (d) obtaining a cell sample from thesubject; (e) contacting the cell sample so obtained with an antibody ofclaim 58; and (f) detecting the presence of the antibody bound to theprotein encoded by said gene.
 64. The method of claim 62 or 63 for thedetection of the expression of a protein encoded by the nucleic acidmolecule of claim
 44. 65. A method for diagnosing in a subject todisorder as defined in any one of claims 1 to 6 or a predisposition tosuch disorder which comprises: (a) isolating DNA from patient sufferingfrom the disorder; (b) digesting the isolated DNA of step (a) with atleast one restriction enzyme; (c) incubating the resulting gel with aprobe comprising a nucleic acid molecule of any one of claims 42 to 49or a fragment thereof labelled with a detectable marker; (d) detectinglabelled bands on a gel which have hybridized to the probe as defined tocreate a band pattern specific to the DNA of patients of the disorder;(e) preparing subject's DNA by steps (a) to (e) to produce detectablelabeled bands on a gel; and (f) comparing the band pattern specific tothe DNA of patients of the disorder of step (e) and the subject's DNA ofstep (f) to determine whether the patterns are the same or different andto diagnose thereby the disorder or a predisposition to the disorder, ifthe patterns are the same.
 66. A method for diagnosing a disorder asdefined in any one of claims 1 to 6 or a predisposition to such adisorder comprising: (a) analyzing a sample of nucleic acids of asubject by means of a diagnostic chip, primer extension, singlenucleotide polymorphisms or sequencing comprising a nucleic acidmolecule of any one of claims 42 to 49, and (b) comparing the resultwith that OF A sample obtained from a patient suffering from thedisorder, wherein the identity of expression profile and/or nucleotidesequence is indicative for the disorder.
 67. Use of an effective dose ofa nucleic acid molecule of any one of claims 42 to 49, or a nucleic acidmolecule which is complementary to such a nucleic acid molecule or avector of claim 50 to 51 for the preparation of a composition fortreating, preventing and/or delaying a disorder as defined in any one ofclaims 1 to 6 in a subject by somatic gene therapy.
 68. A method ofdetermining whether a test substance has an effect on a nucleic acidmolecule or polypeptide involved in a disorder as defined in any one ofclaims 1 to 6, comprising the steps: (a) contacting a cell whichexpresses the polypeptide of claim 57 with a compound to be screened;and (b) determining if the compound modulates the expression or theactivity of said polypeptide.
 69. The method of claim 68, wherein saidpolypeptide is expressed under the control of the GGTB-promoter.
 70. Themethod of claim 68 or 69, wherein the test substance is achemotherapeutic agent.
 71. The method of any one of claims 68 to 70,wherein the test substance is a mixture of chemotherapeutic agents. 72.The method of any one of claims 68 to 71, wherein said cell is derivedfrom a single cell or a multi-cellular organism.
 73. The method of anyone of claims 68 to 72, wherein said cell is a cell as defined in anyone of claims 28, 29, 35 or 52 to
 55. 74. The method of any one of claim68 TO 73, wherein preferably in the first screen said test substance iscomprised in and subjected as a collection of test substances.
 75. Themethod of claim 74, wherein said collection of test substances has adiversity of about 10³ to about 10⁵.
 76. The method of claim 74 or 75,wherein the diversity of said collection of test substances issuccessively reduced.
 77. The method of any one of claims 68 to 76,wherein said cell is comprised in a tissue or in a non-human animal. 78.A method for producing a drug or prodrug for the treatment of a disorderas defined in any one of claim 1 to 6 comprising: (a) synthezising atest substance or a collection of test substances; (b) subjecting saidthe test substance or collection of test substances to the method of anyone of claims 68 to 77; and (c) producing a compound identified as amodulator in step (b) or a derivative thereof.
 79. A test substanceidentified, isolated and/or produced by the method of any one of claims68 to 78, wherein said test substance has hitherto not been known as adrug for the treatment of a disorder as defined in any one of claims 1to
 6. 80. Use of a compound identified, isolated and/or produced by themethod of any one of claims 68 to 78 for the preparation of acomposition for the treatment of a disorder as defined in any one ofclaims 1 to
 6. 81. A method for the treatment of a disorder as definedin any one of claims 1 to 6, comprising administering a compositionprepared according to the use of claim 80 or the method of claim 78 to asubject suffering from the disorder.
 82. A chip comprising a solidsupport and attached thereto one or more of the nucleic acid moleculesof any one of claims 42 to
 49. 83. A kit for use in the method of anyone of claims 24 to 41 or 62 to 78 comprising a chip of claim 82 orother means for the detection of expression and/or activity of a nucleicacid molecule of any one of claims 42 to 49 or a polypeptide of claim58.
 84. Use of a compound identified, isolated and/or produced by themethod of any one of claims 68 to 78 as a lead compound in drugdiscovery and preparation of drugs or prodrugs.
 85. Use of a nucleicacid molecule of any one of claims 42 to 49 or of a polypeptide of claim57 for the validation of test substances, lead compounds, drugs andprodrugs for the treatment of a disorder as defined in any one of claims1 to 6 or for the identification and isolation of downstream genes,which respond to modulation of a gene comprising a nucleic acid moleculeof any one of claims 42 to 49 or its encoded gene product.
 86. Atransgenic non-human animal which displays an aberrant expression oractivity of the polypeptide of claim
 57. 87. The non-human animal ofclaim 86, wherein said animal reproduces a disorder as defined in anyone of claims 1 to
 6. 88. The animal of claim 86 or 87 which is amammal.
 89. Use of a transgenic non-human animal of any one of claims 86to 88 for a process in drug discovery for the treatment of a disorder asdefined in any one of claims 1 to
 6. 90. A pharmaceutical compositionfor use in the treatment of a disorder as defined in any one of claim 1to 6 comprising one or more double-stranded oligoribonucleotides(dsRNA), which mediate an RNA interference of the corresponding mRNA ofone or more nucleic acid molecules of any one of claims 42 to 49, andoptionally a pharmaceutically acceptable carrier.
 91. The nucleic acidmolecule of claim 45 which is cDNA.